BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061] [Cited by in Crossref: 1846] [Cited by in F6Publishing: 1682] [Article Influence: 205.1] [Reference Citation Analysis]
Number Citing Articles
1 Ye H, Zhang C, Wang BJ, Tan XH, Zhang WP, Teng Y, Yang X. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Oncogene. 2014;33:5133-5138. [PMID: 24213574 DOI: 10.1038/onc.2013.468] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
2 Sun C, Sun HY, Xiao WH, Zhang C, Tian ZG. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin. 2015;36:1191-1199. [PMID: 26073325 DOI: 10.1038/aps.2015.41] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 12.2] [Reference Citation Analysis]
3 Klein J, Korol R, Lo SS, Chu W, Lock M, Dorth JA, Ellis RJ, Mayr NA, Huang Z, Chung HT. Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncol 2014;10:2227-41. [PMID: 25471036 DOI: 10.2217/fon.14.167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
4 Tokunaga M, Uto H, Oda K, Tokunaga M, Mawatari S, Kumagai K, Haraguchi K, Oketani M, Ido A, Ohnou N, Utsunomiya A, Tsubouchi H. Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Gastroenterol 2014;49:1567-77. [DOI: 10.1007/s00535-013-0928-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Cai H, Liu G, Zhong J, Zheng K, Xiao H, Li C, Song X, Li Y, Xu C, Wu H, He Z, Zhu Q. Immune Checkpoints in Viral Infections. Viruses 2020;12:E1051. [PMID: 32967229 DOI: 10.3390/v12091051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
6 Liu X, Zhou M, Wang F, Mubarik S, Wang Y, Meng R, Shi F, Wen H, Yu C. Secular Trend of Cancer Death and Incidence in 29 Cancer Groups in China, 1990-2017: A Joinpoint and Age-Period-Cohort Analysis. Cancer Manag Res 2020;12:6221-38. [PMID: 32801868 DOI: 10.2147/CMAR.S247648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Son YS, Ullah HMA, Elfadl AK, Chung MJ, Ghim SG, Kim YD, Lee EJ, Kang KK, Jeong KS. Preventive Effects of Vitamin C on Diethylnitrosamine-induced Hepatotoxicity in Smp30 Knockout Mice. In Vivo 2018;32:93-9. [PMID: 29275304 DOI: 10.21873/invivo.11209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Huang S, Jiang F, Wang Y, Yu Y, Ren S, Wang X, Yin P, Lou J. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. Tumour Biol 2017;39:1010428317705763. [PMID: 28621228 DOI: 10.1177/1010428317705763] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
9 Mikulic D, Mrzljak A. Liver transplantation and aging. World J Transplant 2020;10:256-66. [PMID: 32995320 DOI: 10.5500/wjt.v10.i9.256] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu Q, Liu N, Shangguan Q, Zhang F, Chai W, Tong X, Zhao X, Li Z, Qi D, Ye X. LncRNA SAMD12-AS1 promotes cell proliferation and inhibits apoptosis by interacting with NPM1. Sci Rep 2019;9:11593. [PMID: 31406141 DOI: 10.1038/s41598-019-48116-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
11 Aljumah AA, Kuriry H, Faisal N, Alghamdi H. Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection. Ann Saudi Med 2018;38:358-65. [PMID: 30284991 DOI: 10.5144/0256-4947.2018.358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186. [PMID: 28042609 DOI: 10.20517/2394-5079.2016.05] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
13 Kim JU, Shariff MI, Crossey MM, Gomez-Romero M, Holmes E, Cox IJ, Fye HK, Njie R, Taylor-Robinson SD. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol. 2016;8:471-484. [PMID: 27057305 DOI: 10.4254/wjh.v8.i10.471] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
14 Qin G, Zhao C, Zhang L, Liu H, Quan Y, Chai L, Wu S, Wang X, Chen T. Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells. Apoptosis 2015;20:1072-86. [PMID: 25935454 DOI: 10.1007/s10495-015-1132-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
15 Miura K, Nagahashi M, Prasoon P, Hirose Y, Kobayashi T, Sakata J, Abe M, Sakimura K, Matsuda Y, Butash AL, Katsuta E, Takabe K, Wakai T. Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine-1-phosphate and ceramide in human hepatocellular carcinoma. Hepatol Res 2021;51:614-26. [PMID: 33586816 DOI: 10.1111/hepr.13625] [Reference Citation Analysis]
16 Cassim S, Raymond VA, Dehbidi-Assadzadeh L, Lapierre P, Bilodeau M. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle 2018;17:903-16. [PMID: 29633904 DOI: 10.1080/15384101.2018.1460023] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
17 Abel L, Alcaïs A, Schurr E. The dissection of complex susceptibility to infectious disease: bacterial, viral and parasitic infections. Curr Opin Immunol 2014;30:72-8. [PMID: 25083600 DOI: 10.1016/j.coi.2014.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
18 Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clin Liver Dis. 2016;20:607-628. [PMID: 27742003 DOI: 10.1016/j.cld.2016.06.006] [Cited by in Crossref: 115] [Cited by in F6Publishing: 87] [Article Influence: 38.3] [Reference Citation Analysis]
19 Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS One 2013;8:e65569. [PMID: 23776502 DOI: 10.1371/journal.pone.0065569] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
20 Nam JY, Lee JH, Kim HY, Kim JE, Lee DH, Chang Y, Cho H, Yoo JJ, Lee M, Cho YY, Cho Y, Cho E, Yu SJ, Kim YJ, Yoon JH. Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS One 2017;12:e0166188. [PMID: 28099520 DOI: 10.1371/journal.pone.0166188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chuma M, Terashita K, Sakamoto N. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatol Res. 2015;45:E1-E11. [PMID: 25472913 DOI: 10.1111/hepr.12459] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
22 Leathers JS, Pisano MB, Re V, Van Oord G, Sultan A, Boonstra A, Debes JD. Evaluation of Rapid Diagnostic Tests for Assessment of Hepatitis B in Resource-Limited Settings. Ann Glob Health 2019;85:98. [PMID: 31276335 DOI: 10.5334/aogh.2562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Rao Q, You A, Guo Z, Zuo B, Gao X, Zhang T, Du Z, Wu C, Yin H. Intrahepatic Tissue Implantation Represents a Favorable Approach for Establishing Orthotopic Transplantation Hepatocellular Carcinoma Mouse Models. PLoS One 2016;11:e0148263. [PMID: 26824903 DOI: 10.1371/journal.pone.0148263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
24 Qiu X, Hu B, Huang Y, Deng Y, Wang X, Zheng F. Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance. Dig Dis Sci 2016;61:149-57. [DOI: 10.1007/s10620-015-3878-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
25 Ezzikouri S, Benjelloun S, Pineau P. Human genetic variation and the risk of hepatocellular carcinoma development. Hepatol Int 2013;7:820-31. [PMID: 26201919 DOI: 10.1007/s12072-013-9463-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
26 Ma X, Gu J, Wang K, Zhang X, Bai J, Zhang J, Liu C, Qiu Q, Qu K. Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection. Sci Rep 2019;9:7073. [PMID: 31068611 DOI: 10.1038/s41598-019-43548-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Han P, Sun D, Yang J. Interaction between periodontitis and liver diseases. Biomed Rep 2016;5:267-76. [PMID: 27588170 DOI: 10.3892/br.2016.718] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
28 Wu Q, Chen X, Wang P, Wu Q, Qi X, Han X, Chen L, Meng X, Xu K. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2020;12:8016-29. [PMID: 31997633 DOI: 10.1021/acsami.9b22802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
29 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhu H, Geng Y, He Q, Li M. miRNAs regulate immune response and signaling during hepatitis C virus infection. Eur J Med Res 2018;23:19. [PMID: 29669594 DOI: 10.1186/s40001-018-0317-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
31 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Yan J, Yang X, Li L, Liu P, Wu H, Liu Z, Li Q, Liao G, Wang X. Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma. Oncol Lett 2017;13:3395-402. [PMID: 28521445 DOI: 10.3892/ol.2017.5934] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
33 Hayes CN, Zhang P, Zhang Y, Chayama K. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Viruses. 2018;10. [PMID: 30274202 DOI: 10.3390/v10100531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
34 Zhang Y, Liu H, Cui M, Liu J, Yi R, Niu Y, Chen T, Zhao Y. Effect of the HBV whole-X gene on the expression of hepatocellular carcinoma associated proteins. J Microbiol Immunol Infect 2016;49:335-43. [PMID: 25311406 DOI: 10.1016/j.jmii.2014.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Allaire M, El Hajj W, Brichler S, Diallo K, Fanica D, Blaise L, Nkontchou G, Grando V, Arbadi F, Nahon P, Ziol M, Nault JC, Ganne-Carrié N. Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West. Clin Res Hepatol Gastroenterol 2021;45:101436. [PMID: 32418851 DOI: 10.1016/j.clinre.2020.03.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403-2412. [PMID: 24155107 DOI: 10.1002/hep.26905] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 13.1] [Reference Citation Analysis]
37 Li Z, Zhao X, Jiang P, Xiao S, Wu G, Chen K, Zhang X, Liu H, Han X, Wang S, Li X. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: A retrospective case-control study. Medicine (Baltimore) 2016;95:e4224. [PMID: 27495026 DOI: 10.1097/MD.0000000000004224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
38 Murakami Y, Sugiyama K, Ebinuma H, Nakamoto N, Ojiro K, Chu PS, Taniki N, Saito Y, Teratani T, Koda Y, Suzuki T, Saito K, Fukasawa M, Ikeda M, Kato N, Kanai T, Saito H. Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells. BMC Cancer 2018;18:680. [PMID: 29940898 DOI: 10.1186/s12885-018-4588-y] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
39 Rao Q, Zuo B, Lu Z, Gao X, You A, Wu C, Du Z, Yin H. Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro. Hepatology. 2016;64:456-472. [PMID: 26990897 DOI: 10.1002/hep.28549] [Cited by in Crossref: 110] [Cited by in F6Publishing: 110] [Article Influence: 22.0] [Reference Citation Analysis]
40 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
41 Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33. [PMID: 31145929 DOI: 10.1016/j.jhep.2019.05.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 17.5] [Reference Citation Analysis]
42 Wang Z, Qu K, Niu W, Lin T, Xu X, Huang Z, Liu S, Liu S, Chang H, Liu Y, Dong X, Liu C, Zhang Y. Glutathione S-transferase P1 gene rs4147581 polymorphism predicts overall survival of patients with hepatocellular carcinoma: evidence from an enlarged study. Tumour Biol 2016;37:943-52. [PMID: 26260272 DOI: 10.1007/s13277-015-3871-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
43 Guo M, Wang H, Xu S, Zhuang Y, An J, Su C, Xia Y, Chen J, Xu ZZ, Liu Q, Wang J, Dan Z, Chen K, Luan X, Liu Z, Liu K, Zhang F, Xia Y, Liu X. Alteration in gut microbiota is associated with dysregulation of cytokines and glucocorticoid therapy in systemic lupus erythematosus. Gut Microbes 2020;11:1758-73. [PMID: 32507008 DOI: 10.1080/19490976.2020.1768644] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
44 Mu H, Lin KX, Zhao H, Xing S, Li C, Liu F, Lu HZ, Zhang Z, Sun YL, Yan XY. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J Gastroenterol. 2014;20:5826-5838. [PMID: 24914343 DOI: 10.3748/wjg.v20.i19.5826] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
45 Tung CH, Lai NS, Lu MC, Lee CC. Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan. Rheumatol Int 2016;36:199-205. [PMID: 26408009 DOI: 10.1007/s00296-015-3369-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
46 Fujita K, Kuroda N, Morishita A, Oura K, Tadokoro T, Nomura T, Yoneyama H, Arai T, Himoto T, Watanabe S, Masaki T. Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection. J Clin Med. 2018;7. [PMID: 30208564 DOI: 10.3390/jcm7090267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
47 Abdel Allah HMM, Zahran WE, El-Masry SA, El-Bendary M, Soliman AF. Association of MTHFR and TYMS gene polymorphisms with the susceptibility to HCC in Egyptian HCV cirrhotic patients. Clin Exp Med 2021. [PMID: 34297238 DOI: 10.1007/s10238-021-00747-3] [Reference Citation Analysis]
48 Okamura S, Sumie S, Tonan T, Nakano M, Satani M, Shimose S, Shirono T, Iwamoto H, Aino H, Niizeki T, Tajiri N, Kuromatsu R, Okuda K, Nakashima O, Torimura T. Diffusion-weighted magnetic resonance imaging predicts malignant potential in small hepatocellular carcinoma. Dig Liver Dis 2016;48:945-52. [PMID: 27338850 DOI: 10.1016/j.dld.2016.05.020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
49 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
50 Wei XL, Luo HY, Li CF, Jin Y, Zeng ZL, Ju HQ, Wu QN, Wang Y, Mao MJ, Liu WL, Jia WH, Zhang HZ, Li YH, Wang F, Xu RH. Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. Int J Cancer 2017;141:152-9. [PMID: 28369849 DOI: 10.1002/ijc.30719] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
51 Hatta MNA, Mohamad Hanif EA, Chin SF, Neoh HM. Pathogens and Carcinogenesis: A Review. Biology (Basel) 2021;10:533. [PMID: 34203649 DOI: 10.3390/biology10060533] [Reference Citation Analysis]
52 Stahmeyer JT, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen H, Hüppe D, Teuber G, Wiebner B, Wedemeyer H, Krauth C. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol 2014;26:1278-85. [PMID: 25144493 DOI: 10.1097/MEG.0000000000000181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Haberl EM, Weiss TS, Peschel G, Weigand K, Köhler N, Pauling JK, Wenzel JJ, Höring M, Krautbauer S, Liebisch G, Buechler C. Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:5297. [PMID: 34069902 DOI: 10.3390/ijms22105297] [Reference Citation Analysis]
54 Gutierrez JA, Gish RG. Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res 2013;2:460-71. [PMID: 26504748 DOI: 10.3978/j.issn.2218-676X.2013.10.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Peltrini R, Cantoni V, Green R, Lionetti R, D'Ambra M, Bartolini C, De Luca M, Bracale U, Cuocolo A, Corcione F. Risk of appendiceal neoplasm after interval appendectomy for complicated appendicitis: A systematic review and meta-analysis. Surgeon 2021:S1479-666X(21)00031-7. [PMID: 33640282 DOI: 10.1016/j.surge.2021.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Sheng T, Wang B, Wang SY, Deng B, Qu L, Qi XS, Wang XL, Deng GL, Sun X. The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection. Medicine (Baltimore). 2015;94:e941. [PMID: 26091457 DOI: 10.1097/MD.0000000000000941] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
57 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
58 Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Baerlocher MO, Gates VL, Riaz A, Brown DB, Siddiqi NH, Walker TG, Silberzweig JE, Mitchell JW, Nikolic B, Salem R. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology 2017;28:1-15. [DOI: 10.1016/j.jvir.2016.09.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 34] [Article Influence: 13.5] [Reference Citation Analysis]
59 Zhang J, Zong Y, Xu GZ, Xing K. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J 2016;37:1184-90. [PMID: 27761555 DOI: 10.15537/smj.2016.11.16267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
60 Zeng J, Huang X, Zhou L, Tan Y, Hu C, Wang X, Niu J, Wang H, Lin X, Yin P. Metabolomics Identifies Biomarker Pattern for Early Diagnosis of Hepatocellular Carcinoma: from Diethylnitrosamine Treated Rats to Patients. Sci Rep 2015;5:16101. [PMID: 26526930 DOI: 10.1038/srep16101] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
61 Miftahussurur M, Nusi IA, Graham DY, Yamaoka Y. Helicobacter, Hygiene, Atopy, and Asthma. Front Microbiol. 2017;8:1034. [PMID: 28642748 DOI: 10.3389/fmicb.2017.01034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
62 Zhao C, Xing F, Yeo YH, Jin M, Le R, Le M, Jin M, Henry L, Cheung R, Nguyen MH. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:406-19. [PMID: 31490419 DOI: 10.1097/MEG.0000000000001523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
63 Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One. 2013;8:e61448. [PMID: 23613855 DOI: 10.1371/journal.pone.0061448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
64 Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, Jin L, Zhang T, Chen X. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70:674-683. [PMID: 30543829 DOI: 10.1016/j.jhep.2018.12.001] [Cited by in Crossref: 123] [Cited by in F6Publishing: 106] [Article Influence: 41.0] [Reference Citation Analysis]
65 Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol. 2014;11:340-349. [PMID: 24473361 DOI: 10.1038/nrgastro.2014.6] [Cited by in Crossref: 113] [Cited by in F6Publishing: 99] [Article Influence: 16.1] [Reference Citation Analysis]
66 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett. 2013;6:1213-1218. [PMID: 24179497 DOI: 10.3892/ol.2013.1578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
67 Zhang S, Cao L, Li Z, Qu D. Metabolic reprogramming links chronic intestinal inflammation and the oncogenic transformation in colorectal tumorigenesis. Cancer Letters 2019;450:123-31. [DOI: 10.1016/j.canlet.2019.02.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
68 Cusimano A, Puleio R, D'Alessandro N, Loria GR, McCubrey JA, Montalto G, Cervello M. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget 2015;6:1707-22. [PMID: 25596737 DOI: 10.18632/oncotarget.2738] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
69 Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. [PMID: 28975830 DOI: 10.1177/1073274817729245] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 51.7] [Reference Citation Analysis]
70 Nakagawa H, Shibata T. Comprehensive genome sequencing of the liver cancer genome. Cancer Lett 2013;340:234-40. [PMID: 23142287 DOI: 10.1016/j.canlet.2012.10.035] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
71 Colpitts CC, El-Saghire H, Pochet N, Schuster C, Baumert TF. High-throughput approaches to unravel hepatitis C virus-host interactions. Virus Res 2016;218:18-24. [PMID: 26410623 DOI: 10.1016/j.virusres.2015.09.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
72 Rozenblum N, Zeira E, Scaiewicz V, Bulvik B, Gourevitch S, Yotvat H, Galun E, Goldberg SN. Oncogenesis: An "Off-Target" Effect of Radiofrequency Ablation. Radiology 2015;276:426-32. [PMID: 26203709 DOI: 10.1148/radiol.2015141695] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
73 Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647. [PMID: 25397971 DOI: 10.1371/journal.pone.0112647pone-d-14-33428] [Reference Citation Analysis]
74 Wu IC, Liu WC, Chang TT. Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations. J Biomed Sci 2018;25:51. [PMID: 29859540 DOI: 10.1186/s12929-018-0442-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
75 Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2014;20:6252-6261. [PMID: 24876746 DOI: 10.3748/wjg.v20.i20.6252] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
76 Gane EJ, Charlton MR, Mohamed R, Sollano JD, Tun KS, Pham TTT, Payawal DA, Gani RA, Muljono DH, Acharya SK, Zhuang H, Shukla A, Madan K, Saraf N, Tyagi S, Singh KR, Cua IHY, Jargalsaikhan G, Duger D, Sukeepaisarnjaroen W, Purnomo HD, Hasan I, Lesmana LA, Lesmana CRA, Kyi KP, Naing W, Ravishankar AC, Hadigal S. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings. J Viral Hepat 2020;27:466-75. [PMID: 31785182 DOI: 10.1111/jvh.13244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Dusséaux M, Masse-Ranson G, Darche S, Ahodantin J, Li Y, Fiquet O, Beaumont E, Moreau P, Rivière L, Neuveut C, Soussan P, Roingeard P, Kremsdorf D, Di Santo JP, Strick-Marchand H. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver. Gastroenterology 2017;153:1647-1661.e9. [PMID: 28851562 DOI: 10.1053/j.gastro.2017.08.034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
78 Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, Kykalos S, Karamouzis MV, Schizas D. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers (Basel) 2020;12:E2859. [PMID: 33020428 DOI: 10.3390/cancers12102859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
79 Dahl TF, Cowie BC, Biggs BA, Leder K, MacLachlan JH, Marshall C. Health literacy in patients with chronic hepatitis B attending a tertiary hospital in Melbourne: a questionnaire based survey. BMC Infect Dis 2014;14:537. [PMID: 25338513 DOI: 10.1186/1471-2334-14-537] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
80 Ogunwobi OO, Dibba O, Zhu L, Ilboudo A, Tan Y, Fraser MA, Ma GX. Hepatitis B Virus Screening and Vaccination in First-generation African Immigrants: A Pilot Study. J Community Health 2019;44:1037-43. [PMID: 31123877 DOI: 10.1007/s10900-019-00668-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
81 Lee JM, Yang J, Newell P, Singh S, Parwani A, Friedman SL, Nejak-Bowen KN, Monga SP. β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation. Cancer Lett 2014;343:90-7. [PMID: 24071572 DOI: 10.1016/j.canlet.2013.09.020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
82 Omatola CA, Idofe J, Okolo MO, Adejo PO, Maina MM, Oyiguh JA. Seroprevalence of HBV among people living with HIV in Anyigba, Kogi State, Nigeria. Afr Health Sci 2019;19:1938-46. [PMID: 31656477 DOI: 10.4314/ahs.v19i2.17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
83 Niemeyer DJ, Simo KA, Iannitti DA, McKillop IH. Ablation therapy for hepatocellular carcinoma: past, present and future perspectives. Hepat Oncol 2014;1:67-79. [PMID: 30190942 DOI: 10.2217/hep.13.8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
84 Gouveia-Fernandes S. Monocytes and Macrophages in Cancer: Unsuspected Roles. Adv Exp Med Biol 2020;1219:161-85. [PMID: 32130699 DOI: 10.1007/978-3-030-34025-4_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
85 Chen X, Ma Z, Huang Y, He L, Liang C, Shi C, Zhang Z, Liang C, Liu Z. Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts. J Magn Reson Imaging 2017;46:248-56. [PMID: 27783444 DOI: 10.1002/jmri.25527] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
86 Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma. Viruses. 2018;10. [PMID: 30380697 DOI: 10.3390/v10110591] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
87 Yang X, Shi J, Chen X, Jiang Y, Zhao H. Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression. Oncologist 2020;25:470-4. [PMID: 32100934 DOI: 10.1634/theoncologist.2019-0563] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
88 Schäfer G, Blumenthal MJ, Katz AA. Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses 2015;7:2592-617. [PMID: 26008702 DOI: 10.3390/v7052592] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
89 Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanam M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut. 2019;68:1676-1687. [PMID: 31315892 DOI: 10.1136/gutjnl-2018-317811] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
90 Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58:150-157. [PMID: 23389758 DOI: 10.1002/hep.26300] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
91 Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med 2017;6:E111. [PMID: 29186062 DOI: 10.3390/jcm6120111] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
92 Molina-sánchez P, Lujambio A. Experimental Models for Preclinical Research in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 333-58. [DOI: 10.1007/978-3-030-21540-8_16] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Farhadian A, Dounighi NM, Avadi M. Enteric trimethyl chitosan nanoparticles containing hepatitis B surface antigen for oral delivery. Hum Vaccin Immunother 2015;11:2811-8. [PMID: 26158754 DOI: 10.1080/21645515.2015.1053663] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
94 Saxena R, Kaur J. Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015;7:1572-80. [PMID: 26085916 DOI: 10.4254/wjh.v7.i11.1572] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
95 Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E1007. [PMID: 29597259 DOI: 10.3390/ijms19041007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
96 Borentain P, Garcia S, Gregoire E, Vidal V, Ananian P, Ressiot E, Hardwigsen J, Bartoli J, Moulin G, Botta-fridlund D, Le Treut YP, Gerolami R. Transjugular intrahepatic porto-systemic shunt is a risk factor for liver dysplasia but not hepatocellular carcinoma: A retrospective study of explanted livers. Digestive and Liver Disease 2015;47:57-61. [DOI: 10.1016/j.dld.2014.09.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
97 Rybinski B, Franco-Barraza J, Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics 2014;46:223-44. [PMID: 24520152 DOI: 10.1152/physiolgenomics.00158.2013] [Cited by in Crossref: 124] [Cited by in F6Publishing: 97] [Article Influence: 17.7] [Reference Citation Analysis]
98 Lu M, Hu XH, Li Q, Xiong Y, Hu GJ, Xu JJ, Zhao XN, Wei XX, Chang CC, Liu YK, Nan FJ, Li J, Chang TY, Song BL, Li BL. A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. J Mol Cell Biol 2013;5:404-15. [PMID: 24163426 DOI: 10.1093/jmcb/mjt039] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
99 Zhang Y, He Y, Yu H, Ma F, Wu J, Zhang X. Liquiritigenin Protects Rats from Carbon Tetrachloride Induced Hepatic Injury through PGC-1α Pathway. Evid Based Complement Alternat Med. 2015;2015:649568. [PMID: 26199636 DOI: 10.1155/2015/649568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
100 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Effect of nucleoside analog use in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Res. 2014;44:608-620. [PMID: 23701455 DOI: 10.1111/hepr.12169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
101 Chen M, Lu S, Zheng H, Xu M, Song J, Yang W, Weng Q, Zheng L, Fan X, Cheng X, Gao H, Ji J. Identification of the Potential Metabolic Pathways Involved in the Hepatic Tumorigenesis of Rat Diethylnitrosamine-Induced Hepatocellular Carcinoma via 1H NMR-Based Metabolomic Analysis. Biomed Res Int 2019;2019:9367082. [PMID: 30719453 DOI: 10.1155/2019/9367082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Bordi L, Caglioti C, Garbuglia AR, Lapa D, Castilletti C, Taibi C, Capobianchi MR, Lalle E. IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients. PLoS One 2015;10:e0117397. [PMID: 25675103 DOI: 10.1371/journal.pone.0117397] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
103 Park SS, Lee DM, Lim JH, Lee D, Park SJ, Kim HM, Sohn S, Yoon G, Eom YW, Jeong S, Choi EK, Choi KS. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis. Carcinogenesis 2018;39:458-70. [DOI: 10.1093/carcin/bgy003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
104 Mao X, Tey SK, Ko FCF, Kwong EML, Gao Y, Ng IO, Cheung ST, Guan X, Yam JWP. C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Letters 2019;444:60-9. [DOI: 10.1016/j.canlet.2018.12.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
105 Ding Y, Liu K, Xu Y, Zhao Q, Lou S, Xiang X, Yan L, Cao Z, Xie Q, Zhu C, Bao S, Wang H. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. Cancer Med 2020;9:3057-69. [PMID: 32150664 DOI: 10.1002/cam4.2968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
106 Ali N, Chandrakesan P, Nguyen CB, Husain S, Gillaspy AF, Huycke M, Berry WL, May R, Qu D, Weygant N, Sureban SM, Bronze MS, Dhanasekaran DN, Houchen CW. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget 2015;6:20327-44. [PMID: 25948779 DOI: 10.18632/oncotarget.3972] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
107 Okuyama-Dobashi K, Kasai H, Tanaka T, Yamashita A, Yasumoto J, Chen W, Okamoto T, Maekawa S, Watashi K, Wakita T, Ryo A, Suzuki T, Matsuura Y, Enomoto N, Moriishi K. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Sci Rep 2015;5:17047. [PMID: 26592202 DOI: 10.1038/srep17047] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
108 Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 2019;8:1615817. [PMID: 31413923 DOI: 10.1080/2162402X.2019.1615817] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 15.5] [Reference Citation Analysis]
109 Janovec V, Hodek J, Clarova K, Hofman T, Dostalik P, Fronek J, Chlupac J, Chaperot L, Durand S, Baumert TF, Pichova I, Lubyova B, Hirsch I, Weber J. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Sci Rep 2020;10:12767. [PMID: 32728070 DOI: 10.1038/s41598-020-69614-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Khan M, Imam H, Siddiqui A. Subversion of cellular autophagy during virus infection: Insights from hepatitis B and hepatitis C viruses. Liver Res 2018;2:146-56. [PMID: 31803515 DOI: 10.1016/j.livres.2018.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
111 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
112 Yongyu Z, Lewei Y, Jian L, Yuqin S. [ARTICLE WITHDRAWN] MicroRNA-18a Targets IRF2 and CBX7 to Promote Cell Proliferation in Hepatocellular Carcinoma. Oncol Res 2018;26:1327-34. [PMID: 29386090 DOI: 10.3727/096504018X15165493852990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
113 Teng CF, Chang HY, Tsai HW, Hsieh WC, Kuo YH, Su IJ, Lin YJ. Liver regeneration accelerates hepatitis B virus-related tumorigenesis of hepatocellular carcinoma. Mol Oncol 2018;12:1175-87. [PMID: 29729074 DOI: 10.1002/1878-0261.12318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
114 Nam JY, Chang Y, Cho H, Kang SH, Cho YY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. J Viral Hepat 2018;25:552-60. [PMID: 29194870 DOI: 10.1111/jvh.12838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, Gazzola A, Hong T, Ryan M, Knight V, Dev AT, Sood S, Bell S, Paul E, Roberts SK. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. J Viral Hepat 2017;24:982-9. [PMID: 28414893 DOI: 10.1111/jvh.12717] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
116 Qian F, Hu Q, Tian Y, Wu J, Li D, Tao M, Qin L, Shen B, Xie Y. ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis. Int J Biol Sci 2019;15:369-85. [PMID: 30745827 DOI: 10.7150/ijbs.28422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
117 Shih W, Fang C, Chen P. Anti-Viral Treatment and Cancer Control. In: Chang MH, Jeang K, editors. Viruses and Human Cancer. Berlin: Springer Berlin Heidelberg; 2014. pp. 269-90. [DOI: 10.1007/978-3-642-38965-8_14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
118 Wu Y, Li Y, Giovannucci E. Potential Impact of Time Trend of Lifestyle Risk Factors on Burden of Major Gastrointestinal Cancers in China. Gastroenterology 2021:S0016-5085(21)03351-5. [PMID: 34389341 DOI: 10.1053/j.gastro.2021.08.006] [Reference Citation Analysis]
119 Montella M, D'Arena G, Crispo A, Capunzo M, Nocerino F, Grimaldi M, Barbieri A, D'Ursi AM, Tecce MF, Amore A, Galdiero M, Ciliberto G, Giudice A. Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Int J Endocrinol 2015;2015:854530. [PMID: 26491442 DOI: 10.1155/2015/854530] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
120 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
121 Luo AJ, Wang FZ, Luo D, Hu DH, Mao P, Xie WZ, He XF, Kan W, Wang Y. Consumption of vegetables may reduce the risk of liver cancer: results from a meta-analysis of case-control and cohort studies. Clin Res Hepatol Gastroenterol 2015;39:45-51. [PMID: 25212632 DOI: 10.1016/j.clinre.2014.08.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
122 Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0138907. [PMID: 26398404 DOI: 10.1371/journal.pone.0138907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
123 Lupberger J, Duong FH, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB, Heim MH. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology. 2013;58:1225-1235. [PMID: 23519785 DOI: 10.1002/hep.26404] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
124 Huang S, Qing J, Wang S, Wang H, Zhang L, Tang Y. Design and synthesis of imidazo[1,2-α][1,8]naphthyridine derivatives as anti-HCV agents via direct C-H arylation. Org Biomol Chem 2014;12:2344-8. [PMID: 24595428 DOI: 10.1039/c3ob42525h] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
125 Lucca I, Klatte T, Fajkovic H, de Martino M, Shariat SF. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol 2015;12:585-92. [PMID: 26436686 DOI: 10.1038/nrurol.2015.232] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
126 Estevez J, Chen VL, Podlaha O, Li B, Le A, Vutien P, Chang ET, Rosenberg-Hasson Y, Jiang Z, Pflanz S, Ge D, Gaggar A, Nguyen MH. Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma. Sci Rep 2017;7:11867. [PMID: 28928388 DOI: 10.1038/s41598-017-11975-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
127 Sun D, Lu J, Hu C, Zhang Q, Wang X, Zhang Z, Hu S. Prognostic role of miR-760 in hepatocellular carcinoma. Oncol Lett. 2018;16:7239-7244. [PMID: 30546462 DOI: 10.3892/ol.2018.9546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
128 Lu D, Han C, Wu T. 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1. Oncogene 2014;33:1101-12. [PMID: 23542179 DOI: 10.1038/onc.2013.69] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
129 Kong Y, You H, Jia J. Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense. Hepatol Int 2016;10:239-41. [DOI: 10.1007/s12072-016-9714-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
130 Warowicka A, Nawrot R, Goździcka-Józefiak A. Antiviral activity of berberine. Arch Virol 2020;165:1935-45. [PMID: 32594322 DOI: 10.1007/s00705-020-04706-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
131 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
132 Shabani F, Farasat A, Mahdavi M, Gheibi N. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer. Inflamm Res 2018;67:801-12. [PMID: 30083975 DOI: 10.1007/s00011-018-1173-4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 21.3] [Reference Citation Analysis]
133 Aillot L, Bonnin M, Ait-Goughoulte M, Bendriss-Vermare N, Maadadi S, Dimier L, Subic M, Scholtes C, Najera I, Zoulim F, Lucifora J, Durantel D. Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. Antimicrob Agents Chemother 2018;62:e01741-17. [PMID: 29439958 DOI: 10.1128/AAC.01741-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
134 Ahn SB, Powell EE, Russell A, Hartel G, Irvine KM, Moser C, Valery PC. Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. Hepatol Commun. 2020;4:1279-1292. [PMID: 32923832 DOI: 10.1002/hep4.1536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
135 Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, Kwo PY, Harrison SA, Younossi ZM, Ahmed A. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int 2019;39:1661-71. [PMID: 31081997 DOI: 10.1111/liv.14135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
136 Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF. Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection. Viruses 2016;8:E261. [PMID: 27657111 DOI: 10.3390/v8090261] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
137 Perumalswami PV, Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Motamed D, Khaitova V, Chang C, Grewal P, Liu L, Schiano TD, Woodward M, Dieterich DT, Branch AD. High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens. J Viral Hepat 2016;23:667-76. [PMID: 26989855 DOI: 10.1111/jvh.12530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
138 Thilakarathna WPDW, Rupasinghe HPV, Ridgway ND. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:2606. [PMID: 33807605 DOI: 10.3390/ijms22052606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62:1190-1200. [PMID: 26146815 DOI: 10.1002/hep.27969] [Cited by in Crossref: 230] [Cited by in F6Publishing: 219] [Article Influence: 46.0] [Reference Citation Analysis]
140 Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management. Adv Pharmacol. 2013;67:247-291. [PMID: 23886003 DOI: 10.1016/B978-0-12-405880-4.00007-X] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
141 El-tawdi AHF, Matboli M, El-nakeep S, Azazy AEM, Abdel-rahman O. Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2016;10:869-77. [DOI: 10.1080/17474124.2016.1193003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
142 Zhang J, Arena C, Pednekar A, Lambert B, Dees D, Lee VV, Muthupillai R. Short-Term Repeatability of Magnetic Resonance Elastography at 3.0T: Effects of Motion-Encoding Gradient Direction, Slice Position, and Meal Ingestion. J Magn Reson Imaging 2016;43:704-12. [PMID: 26331461 DOI: 10.1002/jmri.25035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
143 Meguro M, Mizuguchi T, Kawamoto M, Ota S, Ishii M, Nishidate T, Okita K, Kimura Y, Hirata K. Clinical comparison of laparoscopic and open liver resection after propensity matching selection. Surgery. 2015;158:573-587. [PMID: 26120070 DOI: 10.1016/j.surg.2015.02.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
144 Yan M, Ha J, Aguilar M, Bhuket T, Liu B, Gish RG, Cheung R, Wong RJ. Birth cohort-specific disparities in hepatocellular carcinoma stage at diagnosis, treatment, and long-term survival. J Hepatol 2016;64:326-32. [PMID: 26386160 DOI: 10.1016/j.jhep.2015.09.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
145 Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal 2014;20:2854-72. [PMID: 24040957 DOI: 10.1089/ars.2013.5619] [Cited by in Crossref: 133] [Cited by in F6Publishing: 111] [Article Influence: 19.0] [Reference Citation Analysis]
146 Mazzoccoli G, Vinciguerra M, Carbone A, Relógio A. The Circadian Clock, the Immune System, and Viral Infections: The Intricate Relationship Between Biological Time and Host-Virus Interaction. Pathogens 2020;9:E83. [PMID: 32012758 DOI: 10.3390/pathogens9020083] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
147 Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int 2016;36:1196-205. [PMID: 26901163 DOI: 10.1111/liv.13096] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
148 Barry AE, Baldeosingh R, Lamm R, Patel K, Zhang K, Dominguez DA, Kirton KJ, Shah AP, Dang H. Hepatic Stellate Cells and Hepatocarcinogenesis. Front Cell Dev Biol 2020;8:709. [PMID: 32850829 DOI: 10.3389/fcell.2020.00709] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
149 Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer. 2012;1:226-237. [PMID: 24159587 DOI: 10.1159/000343837] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
150 Delacourt AT, Mehta AS. Liver Cancer (Current Therapies). Reference Module in Biomedical Sciences. Elsevier; 2021. [DOI: 10.1016/b978-0-12-820472-6.00007-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Zhang L, Xu K, Liu C, Chen J. Meta-analysis reveals an association of STAT4 polymorphism with hepatocellular carcinoma risk. Hepatol Res. 2016; Epub ahead of print. [PMID: 27126090 DOI: 10.1111/hepr.12733] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
152 Sartorius K, Makarova J, Sartorius B, An P, Winkler C, Chuturgoon A, Kramvis A. The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis. Cells 2019;8:E1504. [PMID: 31771261 DOI: 10.3390/cells8121504] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
153 Jarret A, McFarland AP, Horner SM, Kell A, Schwerk J, Hong M, Badil S, Joslyn RC, Baker DP, Carrington M, Hagedorn CH, Gale M Jr, Savan R. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med 2016;22:1475-81. [PMID: 27841874 DOI: 10.1038/nm.4211] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
154 Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-285. [PMID: 29551708 DOI: 10.1016/j.jhep.2018.02.032] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 17.7] [Reference Citation Analysis]
155 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 2019;25:1550-1559. [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 29] [Article Influence: 19.0] [Reference Citation Analysis]
156 Araujo OC, Barros JJ, do Ó KM, Nabuco LC, Luz CA, Perez RM, Niel C, Villela-Nogueira CA, Araujo NM. Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma. J Med Virol. 2014;86:217-223. [PMID: 24338810 DOI: 10.1002/jmv.23837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
157 Lee SY, Choi YM, Oh SJ, Yang SB, Lee J, Choe WH, Kook YH, Kim BJ. rt269I Type of Hepatitis B Virus (HBV) Leads to HBV e Antigen Negative Infections and Liver Disease Progression via Mitochondrial Stress Mediated Type I Interferon Production in Chronic Patients With Genotype C Infections. Front Immunol 2019;10:1735. [PMID: 31402915 DOI: 10.3389/fimmu.2019.01735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
158 Huan L, Liang LH, He XH. Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med 2016;13:407-25. [PMID: 28154773 DOI: 10.20892/j.issn.2095-3941.2016.0071] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
159 Yao M, Wang L, Yao Y, Gu HB, Yao DF. Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma. J Clin Transl Hepatol. 2014;2:253-258. [PMID: 26355266 DOI: 10.14218/jcth.2014.00020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
160 He H, Ji B, Jia Z, Zhang Y, Wang X, Tao X, Liu Y, Jiang J. A Practical Model is Equivalent to the BALAD or BALAD-2 Score in Predicting Long-term Survival after Hepatectomy in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:1474-82. [PMID: 33531992 DOI: 10.7150/jca.51593] [Reference Citation Analysis]
161 Oura K, Fujita K, Morishita A, Iwama H, Nakahara M, Tadokoro T, Sakamoto T, Nomura T, Yoneyama H, Mimura S, Tani J, Kobara H, Okano K, Suzuki Y, Masaki T. Serum microRNA-125a-5p as a potential biomarker of HCV-associated hepatocellular carcinoma. Oncol Lett 2019;18:882-90. [PMID: 31289566 DOI: 10.3892/ol.2019.10385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
162 Wang S, Deng Y, Yu X, Zhang XW, Huo CL, Sun ZG, Chang H. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram. Sci Rep 2021;11:13814. [PMID: 34226605 DOI: 10.1038/s41598-021-93289-3] [Reference Citation Analysis]
163 Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, Raffa G, Sangiovanni A, Navarra G, Raimondo G, Pollicino T. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7. [DOI: 10.1111/liv.12807] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
164 Shin JH, Yu E, Kim EN, Kim CJ. C-reactive Protein Overexpression in the Background Liver of Hepatitis B Virus-Associated Hepatocellular Carcinoma Is a Prognostic Biomarker. J Pathol Transl Med 2018;52:267-74. [PMID: 30056637 DOI: 10.4132/jptm.2018.07.14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Li H, Li Y, Lu JW, Huo X, Gong Z. Liver-specific androgen receptor knockout attenuates early liver tumor development in zebrafish. Sci Rep 2019;9:10645. [PMID: 31337771 DOI: 10.1038/s41598-019-46378-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
166 van Elsland D, Neefjes J. Bacterial infections and cancer. EMBO Rep. 2018;19. [PMID: 30348892 DOI: 10.15252/embr.201846632] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
167 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 257] [Article Influence: 44.8] [Reference Citation Analysis]
168 Estevez J, Yang JD, Leong J, Nguyen P, Giama NH, Zhang N, Ali HA, Lee M, Cheung R, Roberts L, Schwartz M, Nguyen MH. Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma. Am J Gastroenterol 2019;114:80-8. [DOI: 10.1038/s41395-018-0261-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
169 Schütte K, Balbisi F, Malfertheiner P. Prevention of Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:37-43. [PMID: 27722155 DOI: 10.1159/000446680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
170 Hu Z, Xin H, Luo C, Li J, Zhou Z, Zou J, Zhou S. Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:377-89. [DOI: 10.1007/s00262-020-02685-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
171 Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. [PMID: 30213667 DOI: 10.1016/j.mam.2018.09.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 40.3] [Reference Citation Analysis]
172 Wang MD, Li C, Liang L, Xing H, Sun LY, Quan B, Wu H, Xu XF, Wu MC, Pawlik TM, Lau WY, Shen F, Yang T. Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Oncologist 2020;25:e1541-51. [PMID: 32472951 DOI: 10.1634/theoncologist.2019-0944] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
173 Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. Can J Gastroenterol Hepatol 2017;2017:3268650. [PMID: 28529936 DOI: 10.1155/2017/3268650] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
174 Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017;32:1975-1981. [PMID: 28295594 DOI: 10.1111/jgh.13783] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
175 Huang W, Skanderup AJ, Lee CG. Advances in genomic hepatocellular carcinoma research. Gigascience. 2018;7. [PMID: 30521023 DOI: 10.1093/gigascience/giy135] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
176 Rachel M, Barbara C, Murphy C, Komujuni C, Nyakato P, Ocama P, Lamorde M, Easterbrook P, Ratanshi RP. Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting. Hepatol Med Policy 2018;3:3. [PMID: 30288326 DOI: 10.1186/s41124-017-0030-3] [Reference Citation Analysis]
177 Byam J, Renz J, Millis JM. Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2013;2:22-30. [PMID: 24570911 DOI: 10.3978/j.issn.2304-3881.2012.11.03] [Cited by in F6Publishing: 33] [Reference Citation Analysis]
178 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol. 2015;7:1913-1920. [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
179 Finch ML, Marquardt JU, Yeoh GC, Callus BA. Regulation of microRNAs and their role in liver development, regeneration and disease. Int J Biochem Cell Biol. 2014; Apr 13. [Epub ahead of print]. [PMID: 24731940 DOI: 10.1016/j.biocel.2014.04.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
180 Li L, Liu X, Zhou L, Wang W, Liu Z, Cheng Y, Li J, Wei H. Autophagy Plays a Critical Role in Insulin Resistance- Mediated Chemoresistance in Hepatocellular Carcinoma Cells by Regulating the ER Stress. J Cancer 2018;9:4314-24. [PMID: 30519335 DOI: 10.7150/jca.27943] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
181 Yao J, Shan H, Chen Y, Jiang ZG, Dai XW, Ren JJ, Xu KJ, Ruan B, Yang SG, Li Q. The one year effects of three doses of hepatitis B vaccine as a booster in anti-HBs-negative children 11-15 years after primary immunization; China, 2009-2011. Hum Vaccin Immunother 2015;11:1114-9. [PMID: 25692413 DOI: 10.4161/21645515.2014.987001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
182 [DOI: 10.1101/208330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
183 Fabrício-Silva GM, Poschetzky BS, de Mello Perez R, Dos Santos RC, Cavalini LT, Porto LC. Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro, Brazil. Hepat Med 2015;7:71-9. [PMID: 26586969 DOI: 10.2147/HMER.S89447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
184 Dezhbord M, Lee S, Kim W, Seong BL, Ryu WS. Characterization of the molecular events of covalently closed circular DNA synthesis in de novo Hepatitis B virus infection of human hepatoma cells. Antiviral Res 2019;163:11-8. [PMID: 30639437 DOI: 10.1016/j.antiviral.2019.01.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
185 Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, Li Y, Deng M, Wang C, Liu X, Li L. Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern Asian Countries (1983-2007) and Predictions to 2030. Gastroenterology 2018;154:1719-1728.e5. [PMID: 29549041 DOI: 10.1053/j.gastro.2018.01.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
186 Yu R, Ding S, Tan W, Tan S, Tan Z, Xiang S, Zhou Y, Mao Q, Deng G. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat Mon. 2015;15:e28806. [PMID: 26300931 DOI: 10.5812/hepatmon.28806v2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
187 Buivydiene A, Liakina V, Kashuba E, Norkuniene J, Jokubauskiene S, Gineikiene E, Valantinas J. Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. Medicina (Kaunas) 2018;54:E67. [PMID: 30344298 DOI: 10.3390/medicina54050067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
188 Li L, Li B, Zhang M. HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. Medicine (Baltimore) 2019;98:e16308. [PMID: 31277172 DOI: 10.1097/MD.0000000000016308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Underhill GH, Khetani SR. Emerging trends in modeling human liver disease in vitro. APL Bioeng 2019;3:040902. [PMID: 31893256 DOI: 10.1063/1.5119090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
190 Huang ZL, Li W, Chen QF, Wu PH, Shen LJ. Eight key long non-coding RNAs predict hepatitis virus positive hepatocellular carcinoma as prognostic targets. World J Gastrointest Oncol 2019;11:983-97. [PMID: 31798779 DOI: 10.4251/wjgo.v11.i11.983] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
191 Baravelli CM, Sandberg S, Aarsand AK, Tollånes MC. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet J Rare Dis 2019;14:77. [PMID: 30944007 DOI: 10.1186/s13023-019-1051-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
192 Kuo YH, Wang JH, Chang KC, Hung CH, Lu SN, Hu TH, Yen YH, Kee KM, Chen CH. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs 2020;38:202-10. [PMID: 31701431 DOI: 10.1007/s10637-019-00870-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
193 Chen J, Liu J, Jin R, Shen J, Liang Y, Ma R, Lin H, Liang X, Yu H, Cai X. Cytoplasmic and/or nuclear expression of β-catenin correlate with poor prognosis and unfavorable clinicopathological factors in hepatocellular carcinoma: a meta-analysis. PLoS One. 2014;9:e111885. [PMID: 25401330 DOI: 10.1371/journal.pone.0111885] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
194 Tachi K, Agyei-Nkansah A, Archampong T. Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. Pan Afr Med J 2020;36:43. [PMID: 32774619 DOI: 10.11604/pamj.2020.36.43.21085] [Reference Citation Analysis]
195 Zheng Z, Sze CW, Keng CT, Al-Haddawi M, Liu M, Tan SY, Kwek HL, Her Z, Chan XY, Barnwal B, Loh E, Chang KTE, Tan TC, Tan YJ, Chen Q. Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One 2017;12:e0184127. [PMID: 28886065 DOI: 10.1371/journal.pone.0184127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
196 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
197 Wang X, Gao Y, Li Y, Huang Y, Zhu Y, Lv W, Wang R, Gou L, Cheng C, Feng Z, Xie J, Tian J, Yao R. Roseotoxin B alleviates cholestatic liver fibrosis through inhibiting PDGF-B/PDGFR-β pathway in hepatic stellate cells. Cell Death Dis 2020;11:458. [PMID: 32541811 DOI: 10.1038/s41419-020-2575-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
198 Pohlmann S, Scheu S, Ziegler V, Schupp N, Henninger C, Fritz G. Hepatic Rac1 GTPase contributes to liver-mediated basal immune homeostasis and LPS-induced endotoxemia. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2018;1865:1277-92. [DOI: 10.1016/j.bbamcr.2018.06.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
199 Chen M, Wong CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer 2020;19:44. [PMID: 32111216 DOI: 10.1186/s12943-020-01172-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 48.0] [Reference Citation Analysis]
200 Öcal O, Kupčinskas J, Morkunas E, Amthauer H, Schütte K, Malfertheiner P, Klümpen HJ, Sengel C, Benckert J, Seidensticker R, Sangro B, Wildgruber M, Pech M, Bartenstein P, Ricke J, Seidensticker M. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Res 2021;11:51. [PMID: 34080071 DOI: 10.1186/s13550-021-00791-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94:e688. [PMID: 25860213 DOI: 10.1097/md.0000000000000688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
202 Molla S, Munshea A, Nibret E. Seroprevalence of hepatitis B surface antigen and anti HCV antibody and its associated risk factors among pregnant women attending maternity ward of Felege Hiwot Referral Hospital, northwest Ethiopia: a cross-sectional study. Virol J 2015;12:204. [PMID: 26626263 DOI: 10.1186/s12985-015-0437-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
203 Tan X, Ding Y, Zhu P, Dou R, Liang Z, Yang D, Huang Z, Wang W, Wu X, Weng X. Elevated Hepatic CD1d Levels Coincide with Invariant NKT Cell Defects in Chronic Hepatitis B Virus Infection. J I 2018;200:3530-8. [DOI: 10.4049/jimmunol.1701801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
204 Zhao X, Hu S, Wang L, Zhang Q, Zhu X, Zhao H, Wang C, Tao R, Guo S, Wang J, Xu J, He Y, Gao Y. Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations. PLoS One 2014;9:e106841. [PMID: 25198338 DOI: 10.1371/journal.pone.0106841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
205 Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health. 2013;16:760-768. [PMID: 23947969 DOI: 10.1016/j.jval.2013.03.1630] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
206 Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc 2021;120:621-8. [PMID: 32718890 DOI: 10.1016/j.jfma.2020.07.019] [Reference Citation Analysis]
207 Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 2018;15:4465-76. [PMID: 29731831 DOI: 10.3892/etm.2018.5959] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
208 Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol. 2016;22:1461-1476. [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 54] [Article Influence: 16.0] [Reference Citation Analysis]
209 Wan LF, Shen JJ, Wang YH, Zhao W, Fang NY, Yuan X, Xue BY. Extracts of Qizhu decoction inhibit hepatitis and hepatocellular carcinoma in vitro and in C57BL/6 mice by suppressing NF-κB signaling. Sci Rep 2019;9:1415. [PMID: 30723284 DOI: 10.1038/s41598-018-38391-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
210 Schiller JT, Lowy DR. Virus infection and human cancer: an overview. Recent Results Cancer Res 2014;193:1-10. [PMID: 24008290 DOI: 10.1007/978-3-642-38965-8_1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
211 Mathatha ED, Manamela JM, Musekiwa A, Prabdial-Sing N. Exploring the knowledge, attitudes and practices (KAP) of health care professionals on viral hepatitis notification in Gauteng, South Africa, 2015. Arch Public Health 2018;76:75. [PMID: 30555693 DOI: 10.1186/s13690-018-0319-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, Sauce E, Barget N, Bedossa P, Terris B, Selves J, Bioulac-Sage P, Sturm N, Sattonnet C, Nahon P, Roudot-Thoraval F, Ziol M; ANRS CO12 CirVir Group. Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort). Hepatology 2018;68:1534-48. [PMID: 29637581 DOI: 10.1002/hep.29927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
213 Li S, Wang Z, Li Y, Ding G. Adaptive evolution of proteins in hepatitis B virus during divergence of genotypes. Sci Rep 2017;7:1990. [PMID: 28512348 DOI: 10.1038/s41598-017-02012-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
214 Kakarla R, Liu J, Naduthambi D, Chang W, Mosley RT, Bao D, Steuer HM, Keilman M, Bansal S, Lam AM, Seibel W, Neilson S, Furman PA, Sofia MJ. Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives. J Med Chem 2014;57:2136-60. [PMID: 24476391 DOI: 10.1021/jm4012643] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
215 Fernández I, Pascasio JM, Colmenero J; en nombre del grupo de trabajo para el VII consenso de la SETH., Autores participantes en el grupo de trabajo en representación de sus respectivos programas de trasplante hepático. Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 2020;43:169-77. [PMID: 32094045 DOI: 10.1016/j.gastrohep.2019.11.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer. 2014;120:2150-2157. [PMID: 24723129 DOI: 10.1002/cncr.28706] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
217 Wen Y, Zhou X, Lu M, He M, Tian Y, Liu L, Wang M, Tan W, Deng Y, Yang X, Mayer MP, Zou F, Chen X. Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma. Oncogene 2019;38:1845-59. [PMID: 30367150 DOI: 10.1038/s41388-018-0552-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
218 Sartorius K, Swadling L, An P, Makarova J, Winkler C, Chuturgoon A, Kramvis A. The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways. Viruses 2020;12:E746. [PMID: 32664401 DOI: 10.3390/v12070746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
219 Shimizu M, Shirakami Y, Hanai T, Imai K, Suetsugu A, Takai K, Shiraki M, Moriwaki H. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids. Mol Nutr Food Res 2014;58:124-35. [PMID: 24273224 DOI: 10.1002/mnfr.201300538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
220 Ye S, Zhao XY, Hu XG, Li T, Xu QR, Yang HM, Huang DS, Yang L. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. Oncol Rep 2017;37:2215-26. [PMID: 28350084 DOI: 10.3892/or.2017.5494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
221 Cross TJS, Villanueva A, Shetty S, Wilkes E, Collins P, Adair A, Jones RL, Foxton MR, Meyer T, Stern N, Warshow U, Khan N, Prince M, Khakoo S, Alexander GJ, Khan S, Reeves H, Marshall A, Williams R. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol 2016;7:82-9. [PMID: 28840911 DOI: 10.1136/flgastro-2015-100617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
222 Wang J, Wang Q, Yu G, She Q, Zhang W, Zhang J. Correlation Between Liver Stiffness Measured by Shear Wave Elastography and Child-Pugh Classification. J Ultrasound Med 2018;37:2191-9. [PMID: 29476558 DOI: 10.1002/jum.14569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
223 Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gómez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. J Gastroenterol Hepatol 2015;30:1301-8. [PMID: 25777337 DOI: 10.1111/jgh.12942] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
224 Li X, Li Y, States VA, Li S, Zhang X, Martin RC. The effect of black raspberry extracts on MnSOD activity in protection against concanavalin A induced liver injury. Nutr Cancer 2014;66:930-7. [PMID: 24911141 DOI: 10.1080/01635581.2014.922201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
225 Yoh K, Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Ishii A, Iijima H, Matsunaga H, Nakamura H, Nishiguchi S. Comparison of sleep disorders in chronic hepatitis C patients treated with interferon-based therapy and direct acting antivirals using actigraphy: Sleep disorders and actigraphy in CHC. Hepatol Res 2016;46:1358-66. [DOI: 10.1111/hepr.12694] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
226 Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, Follenzi A, Quagliata L, Ledda-Columbano GM, Terracciano L. Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology. 2015;62:851-862. [PMID: 25783764 DOI: 10.1002/hep.27790] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
227 Huang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, Luo Y, Jian Z, Zhou X. lncAKHE enhances cell growth and migration in hepatocellular carcinoma via activation of NOTCH2 signaling. Cell Death Dis 2018;9:487. [PMID: 29706630 DOI: 10.1038/s41419-018-0554-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
228 Seto W, Yuen M. Hepatitis B Virus: Asian Perspective. In: Wong RJ, Gish RG, editors. Clinical Epidemiology of Chronic Liver Diseases. Cham: Springer International Publishing; 2019. pp. 99-116. [DOI: 10.1007/978-3-319-94355-8_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
229 Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Lim TKH, Yeong J, Toh HC, Lee SY, Chan CY, Goh BK, Chung A, Heikenwälder M, Ng IO, Chow P, Albani S, Chew V. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut 2019;68:916-27. [PMID: 29970455 DOI: 10.1136/gutjnl-2018-316510] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 24.7] [Reference Citation Analysis]
230 Wang HQ, Yang J, Yan LN, Zhang XW, Yang JY. Liver resection in hepatitis B related-hepatocellular carcinoma: clinical outcomes and safety in elderly patients. World J Gastroenterol 2014;20:6620-5. [PMID: 24914386 DOI: 10.3748/wjg.v20.i21.6620] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
231 Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 2015;61:1523-32. [PMID: 25644279 DOI: 10.1002/hep.27705] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
232 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
233 Isorce N, Testoni B, Locatelli M, Fresquet J, Rivoire M, Luangsay S, Zoulim F, Durantel D. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res. 2016;130:36-45. [PMID: 26971407 DOI: 10.1016/j.antiviral.2016.03.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
234 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29.epidemiology] [Reference Citation Analysis]
235 Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139:1534-1545. [PMID: 27244487 DOI: 10.1002/ijc.30211] [Cited by in Crossref: 167] [Cited by in F6Publishing: 146] [Article Influence: 33.4] [Reference Citation Analysis]
236 Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M, Liu S, Jiang X, Zheng J, Zhang X, Chen P. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine 2017;19:18-30. [PMID: 28434945 DOI: 10.1016/j.ebiom.2017.04.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
237 Park KJ, Lee J, Park JH, Joh JW, Kwon CH, Kim JW. Adeno-Associated Virus 2-Mediated Hepatocellular Carcinoma is Very Rare in Korean Patients. Ann Lab Med 2016;36:469-74. [PMID: 27374713 DOI: 10.3343/alm.2016.36.5.469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
238 Shi Y, Yang X, Xue X, Sun D, Cai P, Song Q, Zhang B, Qin L. HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:2127-37. [PMID: 32210579 DOI: 10.2147/OTT.S229913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
239 Tholey DM, Hornung B, Enestvedt CK, Chen Y, Naugler WS, Farsad K, Nabavizadeh N, Schlansky B, Ahn J, Jou JH. Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk? BMJ Open Gastroenterol 2017;4:e000157. [PMID: 28944072 DOI: 10.1136/bmjgast-2017-000157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
240 Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL Jr. Rahma OE. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother. 2018;67:161-174. [PMID: 29052780 DOI: 10.1007/s00262-017-2082-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
241 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
242 Cano L, Cerapio JP, Ruiz E, Marchio A, Turlin B, Casavilca S, Taxa L, Marti G, Deharo E, Pineau P, Bertani S. Liver clear cell foci and viral infection are associated with non-cirrhotic, non-fibrolamellar hepatocellular carcinoma in young patients from South America. Sci Rep 2018;8:9945. [PMID: 30061721 DOI: 10.1038/s41598-018-28286-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
243 Lu T, Yang Q, Li M, Zhang J, Zou J, Huang L, Lin J, Jin H, He J. HBV infection and extra-hepatic cancers in adolescents and 20s: A retrospective study in China. Cancer Epidemiol 2018;55:149-55. [PMID: 29980026 DOI: 10.1016/j.canep.2018.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
244 Teng CF, Li TC, Huang HY, Chan WL, Wu HC, Shyu WC, Su IJ, Jeng LB. Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection. PLoS One 2020;15:e0242748. [PMID: 33237972 DOI: 10.1371/journal.pone.0242748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
245 Link T, Iwakuma T. Roles of p53 in extrinsic factor-induced liver carcinogenesis. Hepatoma Res 2017;3:95-104. [PMID: 30123836 DOI: 10.20517/2394-5079.2017.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
246 Richardson AM, Lidbury BA. Enhancement of hepatitis virus immunoassay outcome predictions in imbalanced routine pathology data by data balancing and feature selection before the application of support vector machines. BMC Med Inform Decis Mak 2017;17:121. [PMID: 28806936 DOI: 10.1186/s12911-017-0522-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
247 Eiró N, Altadill A, Juárez LM, Rodríguez M, González LO, Atienza S, Bermúdez S, Fernandez-Garcia B, Fresno-Forcelledo MF, Rodrigo L. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res. 2014;44:769-778. [PMID: 23742263 DOI: 10.1111/hepr.12180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
248 Jing YY, Liu WT, Guo SW, Ye F, Fan QM, Yu GF, Yu DD, Gao L, Sun K, Han ZP, Li R, Yang Y, Zhao QD, Wu MC, Wang HY, Wei LX. Hepatitis B virus (HBV) receptors: Deficiency in tumor results in scant HBV infection and overexpression in peritumor leads to higher recurrence risk. Oncotarget 2015;6:42952-62. [PMID: 26515593 DOI: 10.18632/oncotarget.5518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
249 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
250 Chiba T, Suzuki E, Saito T, Ogasawara S, Ooka Y, Tawada A, Iwama A, Yokosuka O. Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol. 2015;7:2020-2028. [PMID: 26261691 DOI: 10.4254/wjh.v7.i16.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
251 Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH). Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Med Clin (Barc) 2017;149:61-71. [PMID: 28279536 DOI: 10.1016/j.medcli.2016.12.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
252 Kennedy K, Graham SM, Arora N, Shuhart MC, Kim HN. Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis. PLoS One 2018;13:e0204031. [PMID: 30252863 DOI: 10.1371/journal.pone.0204031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
253 Chen T, Hu Y, Ding Q, Yu J, Wang F, Luo F, Zhang XL. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. Virol Sin 2015;30:249-60. [PMID: 26220728 DOI: 10.1007/s12250-015-3605-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
254 Wungu CDK, Ariyanto FC, Prabowo GI, Soetjipto S, Handajani R. Meta-analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma risk. J Viral Hepat 2021;28:61-71. [PMID: 32896077 DOI: 10.1111/jvh.13402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
255 Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020;73:533-9. [PMID: 32151618 DOI: 10.1016/j.jhep.2020.02.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
256 Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34-59. [PMID: 24713005 DOI: 10.1111/jvh.12248] [Cited by in Crossref: 251] [Cited by in F6Publishing: 236] [Article Influence: 35.9] [Reference Citation Analysis]
257 Palmer DH, Johnson PJ. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. Cancer Metastasis Rev 2015;34:497-509. [DOI: 10.1007/s10555-015-9580-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
258 K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P. Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. Dig Liver Dis 2015;47:296-302. [PMID: 25596930 DOI: 10.1016/j.dld.2014.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
259 Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V. The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. Clin Microbiol Infect 2019;25:906.e1-7. [PMID: 30472417 DOI: 10.1016/j.cmi.2018.11.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
260 Cui X, Wei W, Wang C, Qi Y, Qin X, Huang L, Li W. Studies on the correlation between mutation and integration of HBV in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20201988. [PMID: 32797164 DOI: 10.1042/BSR20201988] [Reference Citation Analysis]
261 Chen X, Liao L, Li Y, Huang H, Huang Q, Deng S. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2020;2020:7653506. [PMID: 33102593 DOI: 10.1155/2020/7653506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
262 Nguyen-Dinh SH, Do A, Pham TND, Dao DY, Nguy TN, Chen MS Jr. High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. World J Hepatol 2018;10:116-23. [PMID: 29399285 DOI: 10.4254/wjh.v10.i1.116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
263 Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer. 2013;4:502-513. [PMID: 23901350 DOI: 10.7150/jca.6503] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
264 Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med 2020;382:1018-28. [PMID: 32160663 DOI: 10.1056/NEJMoa1912035] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 54.0] [Reference Citation Analysis]
265 Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F. Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. Oncotarget. 2017;8:15704-15715. [PMID: 28152517 DOI: 10.18632/oncotarget.14944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
266 Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, Mok MT, Szeto LLM, Lun CY, Lung RW, Zhang J, Yu KH, Lee SD, Huang G, Wang CM, Liu J, Yu Z, Yu DY, Chou JL, Huang WH, Feng B, Cheung YS, Lai PB, Tan P, Wong N, Chan MW, Huang TH, Yip KY, Cheng AS, To KF. Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nat Commun 2019;10:335. [PMID: 30659195 DOI: 10.1038/s41467-018-08245-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
267 Yang P, Si A, Yang J, Cheng Z, Wang K, Li J, Xia Y, Zhang B, Pawlik TM, Lau WY, Shen F. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery 2019;165:721-30. [PMID: 30554724 DOI: 10.1016/j.surg.2018.09.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
268 Du ZQ, Zhao JZ, Dong J, Bi JB, Ren YF, Zhang J, Khalid B, Wu Z, Lv Y, Zhang XF, Wu RQ. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study. World J Gastroenterol 2019;25:3798-807. [PMID: 31391774 DOI: 10.3748/wjg.v25.i28.3798] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
269 Cui X, Ludgate L, Ning X, Hu J. Maturation-associated destabilization of hepatitis B virus nucleocapsid. J Virol 2013;87:11494-503. [PMID: 23966388 DOI: 10.1128/JVI.01912-13] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
270 Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015;6:394-402. [PMID: 25767611 DOI: 10.7150/jca.11212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
271 Bei C, Liu S, Yu X, Qiu M, Tang B, Liao W, He S, Yu H. Single Nucleotide Polymorphisms in miR-122 Are Associated with the Risk of Hepatocellular Carcinoma in a Southern Chinese Population. Biomed Res Int 2018;2018:1540201. [PMID: 30662901 DOI: 10.1155/2018/1540201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
272 Aspichueta P. Lipid-rich environment: a key role promoting carcinogenesis in obesity-related non-alcoholic fatty liver disease. Gut 2018;67:1376-7. [PMID: 29540438 DOI: 10.1136/gutjnl-2018-316047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
273 Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. Int J Mol Sci 2016;17:E1618. [PMID: 27669229 DOI: 10.3390/ijms17101618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
274 Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, Zhang XF, Zhang HX, Zhou ZQ, Weng de S, Xia JC. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget 2016;7:16248-61. [PMID: 26919247 DOI: 10.18632/oncotarget.7637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
275 Patten DA, Shetty S. The Role of Stabilin-1 in Lymphocyte Trafficking and Macrophage Scavenging in the Liver Microenvironment. Biomolecules 2019;9:E283. [PMID: 31315308 DOI: 10.3390/biom9070283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
276 Teraoka Y, Kimura T, Aikata H, Daijo K, Osawa M, Honda F, Nakamura Y, Morio K, Morio R, Hatooka M, Kobayashi T, Nakahara T, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Nagata Y, Chayama K. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. Hepatol Res. 2018;48:193-204. [PMID: 28544062 DOI: 10.1111/hepr.12916] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
277 Jiang X, Kanda T, Wu S, Nakamura M, Miyamura T, Nakamoto S, Banerjee A, Yokosuka O. Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity. World J Gastroenterol. 2014;20:7197-7206. [PMID: 24966589 DOI: 10.3748/wjg.v20.i23.7197] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
278 Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Reference Citation Analysis]
279 Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 14.6] [Reference Citation Analysis]
280 Yin C, Li DY, Guo X, Cao HY, Chen YB, Zhou F, Ge NJ, Liu Y, Guo SS, Zhao Z, Yang HS, Xing JL. NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis. Ann Oncol 2019;30:953-62. [PMID: 30887045 DOI: 10.1093/annonc/mdz105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
281 Lee SM, Kim-Ha J, Choi WY, Lee J, Kim D, Lee J, Choi E, Kim YJ. Interplay of genetic and epigenetic alterations in hepatocellular carcinoma. Epigenomics 2016;8:993-1005. [PMID: 27411963 DOI: 10.2217/epi-2016-0027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
282 Fang G, Wang J, Sun X, Xu R, Zhao X, Shao L, Sun C, Wang Y. LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2. Annals of Hepatology 2020;19:535-40. [DOI: 10.1016/j.aohep.2020.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
283 Clark PJ, Stuart KA, Leggett BA, Crawford DH, Boyd P, Fawcett J, Whiteman DC, Baade PD. Remoteness, race and social disadvantage: disparities in hepatocellular carcinoma incidence and survival in Queensland, Australia. Liver Int 2015;35:2584-94. [PMID: 25900432 DOI: 10.1111/liv.12853] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
284 Laniosz V, Lehman JS, Poland GA, Wetter DA. Literature-based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses. Int J Dermatol 2016;55:599-607. [DOI: 10.1111/ijd.13140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
285 Freeland C, Huynh T, Vu N, Nguyen T, Cohen C. Understanding Knowledge and Barriers Related to Hepatitis B for Vietnamese Nail Salon Workers in the City of Philadelphia and Some of Its Environs. J Community Health 2021;46:502-8. [PMID: 32700174 DOI: 10.1007/s10900-020-00878-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun 2017;8:14600. [PMID: 28300057 DOI: 10.1038/ncomms14600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
287 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
288 Sueangoen N, Tantiwetrueangdet A, Panvichian R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci 2020;10:41. [PMID: 32190291 DOI: 10.1186/s13578-020-00407-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
289 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
290 Wang Y, Han M, Liu S, Yuan X, Zhao J, Lu H, Han K, Liang P, Cheng J. S6K1 inhibits HBV replication through inhibiting AMPK-ULK1 pathway and disrupting acetylation modification of H3K27. Life Sci 2021;265:118848. [PMID: 33278383 DOI: 10.1016/j.lfs.2020.118848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
291 Xu Y, Wang Z, Du X, Liu Y, Song X, Wang T, Tan S, Liang X, Gao L, Ma C. Tim-3 blockade promotes iNKT cell function to inhibit HBV replication. J Cell Mol Med 2018;22:3192-201. [PMID: 29602251 DOI: 10.1111/jcmm.13600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
292 Lebedis C, Luna A, Soto JA. Use of magnetic resonance imaging contrast agents in the liver and biliary tract. Magn Reson Imaging Clin N Am 2012;20:715-37. [PMID: 23088947 DOI: 10.1016/j.mric.2012.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
293 Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis. Cold Spring Harb Perspect Med 2020;10:a037366. [PMID: 31501266 DOI: 10.1101/cshperspect.a037366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
294 Yamada HY, Zhang Y, Reddy A, Mohammed A, Lightfoot S, Dai W, Rao CV. Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice. Carcinogenesis. 2015;36:429-440. [PMID: 25740822 DOI: 10.1093/carcin/bgv011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
295 Hung AK, Guy J. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review. World J Gastroenterol. 2015;21:12197-12210. [PMID: 26576104 DOI: 10.3748/wjg.v21.i42.12197] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
296 Thiele M, Gluud LL, Dahl EK, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open 2013;3:e003265. [PMID: 23945731 DOI: 10.1136/bmjopen-2013-003265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
297 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [DOI: 10.1111/jvh.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
298 Sai W, Wang L, Zheng W, Yang J, Pan L, Cai Y, Qiu L, Zhang H, Wu W, Yao D. Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. Hepat Mon. 2015;15:e32918. [PMID: 26977166 DOI: 10.5812/hepatmon.32918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
299 Ghosh S, Bhowmik S, Majumdar S, Goswami A, Chakraborty J, Gupta S, Aggarwal S, Ray S, Chatterjee R, Bhattacharyya S, Dutta M, Datta S, Chowdhury A, Dhali GK, Banerjee S. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha‐fetoprotein. Int J Cancer 2020;147:2934-47. [DOI: 10.1002/ijc.33111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
300 Rickard J, Beilman G, Forrester J, Sawyer R, Stephen A, Weiser TG, Valenzuela J. Surgical Infections in Low- and Middle-Income Countries: A Global Assessment of the Burden and Management Needs. Surg Infect (Larchmt) 2020;21:478-94. [PMID: 31816263 DOI: 10.1089/sur.2019.142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
301 Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC. The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS One. 2013;8:e66457. [PMID: 23805222 DOI: 10.1371/journal.pone.0066457] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
302 Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J, Tang ZY, Zeng ZC. MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. Oncotarget. 2016;7:87246-87256. [PMID: 27893432 DOI: 10.18632/oncotarget.13531] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
303 Enomoto H, Tao L, Eguchi R, Sato A, Honda M, Kaneko S, Iwata Y, Nishikawa H, Imanishi H, Iijima H, Tsujimura T, Nishiguchi S. The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis. Sci Rep 2017;7:12189. [PMID: 28939881 DOI: 10.1038/s41598-017-12414-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
304 Gelu-simeon M, Sobesky R, Haïm-boukobza S, Ostos M, Teicher E, Fontaine H, Salmon-ceron D, Meyer L, Trinchet J, Paule B, Samuel D, Lewin M, Duclos-vallée J. Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? AIDS 2014;28:1379-91. [DOI: 10.1097/qad.0000000000000300] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 3.1] [Reference Citation Analysis]
305 De Benedittis C, Bellan M, Crevola M, Boin E, Barbaglia MN, Mallela VR, Ravanini P, Ceriani E, Fangazio S, Sainaghi PP, Burlone ME, Minisini R, Pirisi M. Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:4216451. [PMID: 32382265 DOI: 10.1155/2020/4216451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
306 Wang XY, Gao F, Sun YR, Bai LL, Ibrahim MM, Wang B, Tang JW. In vivo and in vitro effect of hepatocarcinoma lymph node metastasis by upregulation of Annexin A7 and relevant mechanisms. Tumour Biol 2016;37:911-24. [PMID: 26256045 DOI: 10.1007/s13277-015-3691-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
307 Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43:13-25. [PMID: 28647765 DOI: 10.1007/s00261-017-1209-1] [Cited by in Crossref: 159] [Cited by in F6Publishing: 134] [Article Influence: 79.5] [Reference Citation Analysis]
308 Lenci I, Baiocchi L, Tariciotti L, Di Paolo D, Milana M, Santopaolo F, Manzia TM, Toti L, Svicher V, Tisone G, Perno CF, Angelico M. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression. Liver Transpl. 2016;22:1205-1213. [PMID: 27272189 DOI: 10.1002/lt.24493] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
309 Zeng FY, Zhao KL, Lin LZ, Deng Y, Qin S, Ye JR, Huang ZQ. Gan-Qing-Ning Formula Inhibits the Growth of Hepatocellular Carcinoma by Promoting Apoptosis and Inhibiting Angiogenesis in H22 Tumor-Bearing Mice. Evid Based Complement Alternat Med 2020;2020:6376912. [PMID: 32831873 DOI: 10.1155/2020/6376912] [Reference Citation Analysis]
310 Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC Gastroenterol 2017;17:154. [PMID: 29221441 DOI: 10.1186/s12876-017-0697-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
311 Wang H, Shang X, Wan X, Xiang X, Mao Q, Deng G, Wu Y. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep 2016;6:38180. [PMID: 27905528 DOI: 10.1038/srep38180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
312 Kim HY, Nam JY, Lee J, Lee HA, Chang Y, Lee HY, Cho H, Lee DH, Cho YY, Cho EJ, Yu SJ, Lee JM, Kim YJ, Yoon J. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther 2018;47:1490-501. [DOI: 10.1111/apt.14623] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
313 Xu CJ, Zhang CP, Luo BF, Liu LJ, Wang YZ, Wang XH, He QJ, Zhou SS, Guo WS, Wang JH, Yang RF, Zhang HY, Rao HY, Feng B, Wei L. Prevalence and characterization of hepatitis B and C virus infections in a needle-sharing population in Northern China. BMC Public Health 2015;15:460. [PMID: 25933922 DOI: 10.1186/s12889-015-1808-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
314 Sanda M, Benicky J, Wu J, Wang Y, Makambi K, Ahn J, Smith CI, Zhao P, Zhang L, Goldman R. Increased sialylation of site specific O-glycoforms of hemopexin in liver disease. Clin Proteomics 2016;13:24. [PMID: 27688741 DOI: 10.1186/s12014-016-9125-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
315 Yao J, Zhang X, Li J, Zhao D, Gao B, Zhou H, Gao S, Zhang L. Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-β1/smad3. Cancer Cell Int 2018;18:208. [PMID: 30564064 DOI: 10.1186/s12935-018-0704-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
316 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 948] [Article Influence: 179.3] [Reference Citation Analysis]
317 Luft O, Khattar R, Farrokhi K, Ferri D, Yavorska N, Zhang J, Sadozai H, Adeyi O, Chruscinski A, Levy GA, Selzner N. Inhibition of the Fibrinogen-Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13. Immunology 2018;154:476-89. [PMID: 29341118 DOI: 10.1111/imm.12897] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
318 Piciocchi M, Cardin R, Vitale A, Vanin V, Giacomin A, Pozzan C, Maddalo G, Cillo U, Guido M, Farinati F. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatol Int. 2013;7:1050-1057. [PMID: 26202034 DOI: 10.1007/s12072-013-9481-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
319 Mueller-Breckenridge AJ, Garcia-Alcalde F, Wildum S, Smits SL, de Man RA, van Campenhout MJH, Brouwer WP, Niu J, Young JAT, Najera I, Zhu L, Wu D, Racek T, Hundie GB, Lin Y, Boucher CA, van de Vijver D, Haagmans BL. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts. Sci Rep. 2019;9:18892. [PMID: 31827222 DOI: 10.1038/s41598-019-55445-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
320 Loustaud-Ratti V, Jacques J, Debette-Gratien M, Carrier P. Hepatitis B and elders: An underestimated issue. Hepatol Res. 2016;46:22-28. [PMID: 25651806 DOI: 10.1111/hepr.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
321 Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, Tangkijvanich P. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma: WFA + -M2BP for diagnosis of HBV-related HCC. Hepatol Res 2018;48:872-81. [DOI: 10.1111/hepr.13187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
322 Yang Y, Sun JW, Zhao LG, Bray F, Xiang YB. Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies. Chin J Cancer Res 2015;27:497-508. [PMID: 26543337 DOI: 10.3978/j.issn.1000-9604.2015.10.05] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
323 Mora RA, Ali R, Gabr A, Abouchaleh N, Asadi AA, Kallini JR, Miller FH, Yaghmai V, Mouli S, Thornburg B, Desai K, Riaz A, Lewandowski RJ, Salem R. Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdom Radiol 2018;43:1723-38. [DOI: 10.1007/s00261-017-1391-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
324 Hagiwara S, Nishida N, Park AM, Komeda Y, Sakurai T, Watanabe T, Kudo M. Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. Sci Rep 2017;7:10440. [PMID: 28874700 DOI: 10.1038/s41598-017-10570-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
325 Yang HC, Shih YF, Liu CJ. Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. J Infect Dis 2017;216:S757-64. [PMID: 29156050 DOI: 10.1093/infdis/jix461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
326 Benegiamo G, Mazzoccoli G, Cappello F, Rappa F, Scibetta N, Oben J, Greco A, Williams R, Andriulli A, Vinciguerra M, Pazienza V. Mutual antagonism between circadian protein period 2 and hepatitis C virus replication in hepatocytes. PLoS One 2013;8:e60527. [PMID: 23593233 DOI: 10.1371/journal.pone.0060527] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
327 Liao M, Sun J, Zhang Q, Tang C, Zhou Y, Cao M, Chen T, Hu C, Yu J, Song Y, Li M, Liao W, Zhou Y. A Novel Post-Operative ALRI Model Accurately Predicts Clinical Outcomes of Resected Hepatocellular Carcinoma Patients. Front Oncol 2021;11:665497. [PMID: 34295811 DOI: 10.3389/fonc.2021.665497] [Reference Citation Analysis]
328 Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, Hassanain M, Paraskevas S, Chaudhury P, Tchervenkov JI. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB (Oxford). 2013;15:724-731. [PMID: 23490176 DOI: 10.1111/hpb.12041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
329 Cherqui D, Soubrane O. Laparoscopic Liver Resection: An Ongoing Revolution. Annals of Surgery 2017;265:864-5. [DOI: 10.1097/sla.0000000000002151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
330 Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60:823-831. [PMID: 24841704 DOI: 10.1002/hep.27228] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 12.1] [Reference Citation Analysis]
331 Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marenco S, Grasso A. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. Eur J Gastroenterol Hepatol. 2013;Epub ahead of print. [PMID: 23719564 DOI: 10.1097/meg.0b013e328362dc99] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
332 Ding Y, Yan JL, Fang AN, Zhou WF, Huang L. Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: a meta-analysis based on 24 articles. Oncotarget. 2017;8:66402-66413. [PMID: 29029522 DOI: 10.18632/oncotarget.18949] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
333 Soresi M, Terranova A, Licata A, Serruto A, Montalto G, Brancatelli G, Giannitrapani L. Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. Biomed Res Int 2017;2017:4932759. [PMID: 28638828 DOI: 10.1155/2017/4932759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
334 Li J, Zhou Q, Rong L, Rong D, Yang Y, Hao J, Zhang Z, Ma L, Rao G, Zhou Y, Xiao F, Li C, Wang H, Li YP. Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells. Antiviral Res 2021;193:105136. [PMID: 34252495 DOI: 10.1016/j.antiviral.2021.105136] [Reference Citation Analysis]
335 Ndiaye AA, Fall IS, Lo G, Seck SM, Tall AB, Gueye B, Mbodj AB, Tal-Dia A. HBsAg seroprevalence among Senegalese militaries. Mil Med Res 2015;2:5. [PMID: 26000172 DOI: 10.1186/s40779-015-0032-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
336 Hernanda PY, Pedroza-Gonzalez A, van der Laan LJ, Bröker ME, Hoogduijn MJ, Ijzermans JN, Bruno MJ, Janssen HL, Peppelenbosch MP, Pan Q. Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinogenesis 2013;34:2330-40. [PMID: 23740837 DOI: 10.1093/carcin/bgt210] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
337 Yao S, Johnson C, Hu Q, Yan L, Liu B, Ambrosone CB, Wang J, Liu S. Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations. Oncotarget. 2016;7:40491-40499. [PMID: 27246981 DOI: 10.18632/oncotarget.9636] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
338 Villain P, Gonzalez P, Almonte M, Franceschi S, Dillner J, Anttila A, Park JY, De Vuyst H, Herrero R. European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiology 2015;39:S120-38. [DOI: 10.1016/j.canep.2015.10.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
339 Cucchetti A, Piscaglia F, Cescon M, Serra C, Colecchia A, Maroni L, Venerandi L, Ercolani G, Pinna AD. An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Digestive and Liver Disease 2014;46:257-63. [DOI: 10.1016/j.dld.2013.10.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
340 Birgani MT, Hajjari M, Shahrisa A, Khoshnevisan A, Shoja Z, Motahari P, Farhangi B. Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma. Pathol Oncol Res. 2017; Epub ahead of print. [PMID: 28508329 DOI: 10.1007/s12253-017-0241-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
341 Zhang Y, Ren JS, Shi JF, Li N, Wang YT, Qu C, Zhang Y, Dai M. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer. 2015;15:94. [PMID: 25879744 DOI: 10.1186/s12885-015-1113-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
342 Lin YH, Wu MH, Huang YH, Yeh CT, Lin KH. TUG1 Is a Regulator of AFP and Serves as Prognostic Marker in Non-Hepatitis B Non-Hepatitis C Hepatocellular Carcinoma. Cells 2020;9:E262. [PMID: 31973032 DOI: 10.3390/cells9020262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
343 Liu LY, Ma XZ, Ouyang B, Ings DP, Marwah S, Liu J, Chen AY, Gupta R, Manuel J, Chen XC, Gage BK, Cirlan I, Khuu N, Chung S, Camat D, Cheng M, Sekhon M, Zagorovsky K, Abdou Mohamed MA, Thoeni C, Atif J, Echeverri J, Kollmann D, Fischer S, Bader GD, Chan WCW, Michalak TI, McGilvray ID, MacParland SA. Nanoparticle Uptake in a Spontaneous and Immunocompetent Woodchuck Liver Cancer Model. ACS Nano. 2020;14:4698-4715. [PMID: 32255624 DOI: 10.1021/acsnano.0c00468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
344 Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Netw Open. 2020;3:e2021173. [PMID: 33206188 DOI: 10.1001/jamanetworkopen.2020.21173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
345 Luo T, Chen M, Zhao Y, Wang D, Liu J, Chen J, Luo H, Li L. Macrophage-associated lncRNA ELMO1-AS1: a novel therapeutic target and prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther 2019;12:6203-16. [PMID: 31498334 DOI: 10.2147/OTT.S213833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
346 Wang Y, Ju L, Xiao F, Liu H, Luo X, Chen L, Lu Z, Bian Z. Downregulation of nucleolar and spindle-associated protein 1 expression suppresses liver cancer cell function. Exp Ther Med 2019;17:2969-78. [PMID: 30936967 DOI: 10.3892/etm.2019.7314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
347 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Nakamura Y, Hirooka M, Abe M, Hiasa Y. Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. J Med Virol. 2020;. [PMID: 32374470 DOI: 10.1002/jmv.25984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
348 Wu M, Miao H, Fu R, Zhang J, Zheng W. Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma. Curr Mol Pharmacol 2020;13:261-72. [PMID: 32091349 DOI: 10.2174/1874467213666200224102820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
349 Zhang BL, Ji X, Yu LX, Gao Y, Xiao CH, Liu J, Zhao DX, Le Y, Diao GH, Sun JY, Li GH, Lei GL, Yu P, Wang RL, Wu JZ, Yang PH, Yan J, Li JY, Xu JJ, Zhang SG, Tian H. Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. Oncol Lett 2018;16:6003-12. [PMID: 30344748 DOI: 10.3892/ol.2018.9371] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
350 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
351 Lu J, Qian J, Yin S, Zhou L, Zheng S, Zhang W. Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology. Front Oncol 2020;10:1105. [PMID: 32733807 DOI: 10.3389/fonc.2020.01105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
352 Haznadar M, Diehl CM, Parker AL, Krausz KW, Bowman ED, Rabibhadana S, Forgues M, Bhudhisawasdi V, Gonzalez FJ, Mahidol C, Budhu A, Wang XW, Ruchirawat M, Harris CC. Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 2019;28:1704-11. [PMID: 31358519 DOI: 10.1158/1055-9965.EPI-19-0453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
353 Delshadi R, Bahrami A, McClements DJ, Moore MD, Williams L. Development of nanoparticle-delivery systems for antiviral agents: A review. J Control Release 2021;331:30-44. [PMID: 33450319 DOI: 10.1016/j.jconrel.2021.01.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
354 Wang SC, Li CY, Chang WT, Cheng WC, Yen CH, Tu WY, Lin ZY, Lin CC, Yeh ML, Huang CF, Huang JF, Dai CY, Chuang WL, Chen YL, Yu ML. Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence. Liver Int 2021;41:956-68. [PMID: 33346937 DOI: 10.1111/liv.14772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
355 Wang J, Li J, Chen L, Fan Z, Cheng J. MicroRNA-499 Suppresses the Growth of Hepatocellular Carcinoma by Downregulating Astrocyte Elevated Gene-1. Technol Cancer Res Treat 2020;19:1533033820920253. [PMID: 32691684 DOI: 10.1177/1533033820920253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Yeh DW, Huang LR, Chen YW, Huang CF, Chuang TH. Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res 2016;2016:4368101. [PMID: 28116318 DOI: 10.1155/2016/4368101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
357 Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013;8:371-380. [PMID: 23662157 DOI: 10.2217/fvl.13.11] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 9.6] [Reference Citation Analysis]
358 Virlogeux V, Pradat P, Hartig-lavie K, Bailly F, Maynard M, Ouziel G, Poinsot D, Lebossé F, Ecochard M, Radenne S, Benmakhlouf S, Koffi J, Lack P, Scholtes C, Uhres A, Ducerf C, Mabrut J, Rode A, Levrero M, Combet C, Merle P, Zoulim F. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int 2017;37:1122-7. [DOI: 10.1111/liv.13456] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 12.0] [Reference Citation Analysis]
359 Zheng Y, Wang X, Wang H, Yan W, Zhang Q, Chang X. Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway. Tumour Biol 2014;35:5189-98. [PMID: 24573607 DOI: 10.1007/s13277-014-1673-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
360 Ma L, Wang X, Jia T, Wei W, Chua MS, So S. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget. 2015;6:25390-25401. [PMID: 26246473 DOI: 10.18632/oncotarget.4455] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 10.2] [Reference Citation Analysis]
361 Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61:S14-S25. [PMID: 25443342 DOI: 10.1016/j.jhep.2014.06.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 143] [Article Influence: 24.3] [Reference Citation Analysis]
362 Sun B, Huang Z, Wang B, Yu Y, Lin S, Luo L, Wang Y, Huang Z. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis. Med Sci Monit 2017;23:850-5. [PMID: 28207681 DOI: 10.12659/msm.899198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
363 Rao S, Hossain T, Mahmoudi T. 3D human liver organoids: An in vitro platform to investigate HBV infection, replication and liver tumorigenesis. Cancer Lett 2021;506:35-44. [PMID: 33675983 DOI: 10.1016/j.canlet.2021.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
364 Ali N, Allam H, Bader T, May R, Basalingappa KM, Berry WL, Chandrakesan P, Qu D, Weygant N, Bronze MS. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One. 2013;8:e80304. [PMID: 24260365 DOI: 10.1371/journal.pone.0080304] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
365 Liu GM, Huang XY, Shen SL, Hu WJ, Peng BG. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. Hepatol Res. 2016;46:100-110. [PMID: 26331530 DOI: 10.1111/hepr.12584] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
366 Hossain MG, Ueda K. Investigation of a Novel Hepatitis B Virus Surface Antigen (HBsAg) Escape Mutant Affecting Immunogenicity. PLoS One 2017;12:e0167871. [PMID: 28045894 DOI: 10.1371/journal.pone.0167871] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
367 Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget. 2016;7:25087-25102. [PMID: 26943571 DOI: 10.18632/oncotarget.7837] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
368 Seo JH, Kim DH, Cho E, Jun CH, Park SY, Cho SB, Park CH, Kim HS, Choi SK, Rew JS. Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea. In Vivo. 2019;33:145-154. [PMID: 30587615 DOI: 10.21873/invivo.11451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
369 Wang W, Ye Y, Wang T, Zhang F, Geng L, Yu J, Zhou L, Yan S, Zheng S. Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil to lymphocyte ratio. Hepatol Res. 2016;46:899-907. [PMID: 26666880 DOI: 10.1111/hepr.12633] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
370 Karageorgos SA, Stratakou S, Koulentaki M, Voumvouraki A, Mantaka A, Samonakis D, Notas G, Kouroumalis EA. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Ann Gastroenterol 2017;30:357-63. [PMID: 28469367 DOI: 10.20524/aog.2017.0135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
371 Hermos JA, Quach L, Gagnon DR, Weber HC, Altincatal A, Cho K, Lawler EV, Grotzinger KM. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection. Pharmacoepidemiol Drug Saf 2014;23:480-8. [PMID: 24677630 DOI: 10.1002/pds.3585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
372 Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. WJG 2021;27:4818-30. [DOI: 10.3748/wjg.v27.i29.4818] [Reference Citation Analysis]
373 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
374 Petrick JL, Freedman ND, Graubard BI, Sahasrabuddhe VV, Lai GY, Alavanja MC, Beane-Freeman LE, Boggs DA, Buring JE, Chan AT, Chong DQ, Fuchs CS, Gapstur SM, Gaziano JM, Giovannucci EL, Hollenbeck AR, King LY, Koshiol J, Lee IM, Linet MS, Palmer JR, Poynter JN, Purdue MP, Robien K, Schairer C, Sesso HD, Sigurdson AJ, Zeleniuch-Jacquotte A, Wactawski-Wende J, Campbell PT, McGlynn KA. Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. Cancer Epidemiol Biomarkers Prev 2015;24:1398-406. [PMID: 26126626 DOI: 10.1158/1055-9965.EPI-15-0137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 5.2] [Reference Citation Analysis]
375 Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut. 2018;67:1342-1350. [PMID: 28615303 DOI: 10.1136/gutjnl-2017-313832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
376 Wang K, Vella AT. Regulatory T Cells and Cancer: A Two-Sided Story. Immunol Invest 2016;45:797-812. [PMID: 27603750 DOI: 10.1080/08820139.2016.1197242] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
377 Shih S, Huang YT, Yang HI. A multiple mediator analysis approach to quantify the effects of the ADH1B and ALDH2 genes on hepatocellular carcinoma risk. Genet Epidemiol 2018;42:394-404. [PMID: 29600553 DOI: 10.1002/gepi.22120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
378 Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y. Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. American Journal of Roentgenology 2015;205:764-73. [DOI: 10.2214/ajr.15.14825] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
379 Zhao L, Yang Q, Liu J. Clinical Value Evaluation of microRNA-324-3p and Other Available Biomarkers in Patients With HBV Infection-Related Hepatocellular Carcinoma. Open Forum Infect Dis 2021;8:ofab108. [PMID: 34189151 DOI: 10.1093/ofid/ofab108] [Reference Citation Analysis]
380 Liu D, Zhu Y, Pang J, Weng X, Feng X, Guo Y. Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195. J Cell Biochem. 2018;119:1368-1380. [PMID: 28722813 DOI: 10.1002/jcb.26297] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
381 Kruse RL, Shum T, Legras X, Barzi M, Pankowicz FP, Gottschalk S, Bissig KD. In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy. Mol Ther Methods Clin Dev 2017;7:32-41. [PMID: 29018834 DOI: 10.1016/j.omtm.2017.08.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
382 Lee SY, Lee SH, Kim JE, Kim H, Kim K, Kook YH, Kim BJ. Identification of Novel A2/C2 Inter-Genotype Recombinants of Hepatitis B Virus from a Korean Chronic Patient Co-Infected with Both Genotype A2 and C2. Int J Mol Sci. 2017;18:pii: E737. [PMID: 28358313 DOI: 10.3390/ijms18040737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
383 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041-1053. [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
384 Wang Y, Jiang J, Ma H, Han J, Sun Z, Liu Z, Xu Z. Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. Tumor Biol 2014;35:7429-33. [DOI: 10.1007/s13277-014-1971-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
385 Ohkoshi S, Hirono H, Watanabe K, Hasegawa K, Yano M. Contributions of transgenic mouse studies on the research of hepatitis B virus and hepatitis C virus-induced hepatocarcinogenesis. World J Hepatol 2015;7:2834-40. [PMID: 26668695 DOI: 10.4254/wjh.v7.i28.2834] [Reference Citation Analysis]
386 Mitchell JK, McGivern DR. Mechanisms of hepatocarcinogenesis in chronic hepatitis C. Hepat Oncol 2014;1:293-307. [PMID: 30190964 DOI: 10.2217/hep.14.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
387 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol. 2018;10:558-570. [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
388 Knop V, Bergk A, Schlosser B, Thieringer J, van Bömmel F, Frost N, Kintscher U, Berg T. Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. Eur J Gastroenterol Hepatol 2013;25:594-600. [PMID: 23325275 DOI: 10.1097/MEG.0b013e32835cc878] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
389 Murakami E, Wang T, Babusis D, Lepist EI, Sauer D, Park Y, Vela JE, Shih R, Birkus G, Stefanidis D, Kim CU, Cho A, Ray AS. Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620. Antimicrob Agents Chemother 2014;58:1943-51. [PMID: 24419340 DOI: 10.1128/AAC.02350-13] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
390 Yan YP, Su HX, Ji ZH, Shao ZJ, Pu ZS. Epidemiology of Hepatitis B Virus Infection in China: Current Status and Challenges. J Clin Transl Hepatol. 2014;2:15-22. [PMID: 26356070 DOI: 10.14218/jcth.2013.00030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
391 Sonnenblick A, Zahavi T. Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment. Biomed Rep 2017;6:545-8. [PMID: 28515912 DOI: 10.3892/br.2017.882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
392 Chen LB, An Z, Zheng HK, Wang XP, Shan RT, Mao CY, Zhang WQ. MicroRNA-34c suppresses proliferation of vascular smooth muscle cell via modulating high mobility group box protein 1. J Clin Lab Anal 2020;34:e23293. [PMID: 32157741 DOI: 10.1002/jcla.23293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
393 Tang X, Cao T, Zhu Y, Zhang L, Chen J, Liu T, Ming X, Fang S, Yuan YF, Jiang L, Huang JD, Guan XY. PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway. Cell Death Dis 2020;11:510. [PMID: 32641749 DOI: 10.1038/s41419-020-2700-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
394 Amstutz A, Nsakala BL, Cheleboi M, Lejone TI, Hobbins MA, Battegay M, Klimkait T, Labhardt ND. Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: A multicenter screening study in Lesotho. J Med Virol 2020. [PMID: 32369206 DOI: 10.1002/jmv.25970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Leong K, Kuppasani K, Pyrsopoulos N. Atrial tumor thrombus: A rare complication of hepatocellular carcinoma. Journal of the American Academy of Physician Assistants 2019;32:23-6. [DOI: 10.1097/01.jaa.0000552723.65316.80] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
396 Hung TH, Liang CM, Hsu CN, Tai WC, Tsai KL, Ku MK, Wang JW, Tseng KL, Yuan LT, Nguang SH, Yang SC, Wu CK, Hsu PI, Wu DC, Chuah SK. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan. PLoS One. 2017;12:e0181858. [PMID: 28742130 DOI: 10.1371/journal.pone.0181858] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
397 Xia Y, Cheng X, Li Y, Valdez K, Chen W, Liang TJ. Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype. J Virol 2018;92:e00722-18. [PMID: 30021897 DOI: 10.1128/JVI.00722-18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
398 Wei J, Fang D. Endoplasmic Reticulum Stress Signaling and the Pathogenesis of Hepatocarcinoma. Int J Mol Sci 2021;22:1799. [PMID: 33670323 DOI: 10.3390/ijms22041799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
399 Marquardt JU, Edlich F. Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies. Front Oncol 2019;9:1421. [PMID: 31921676 DOI: 10.3389/fonc.2019.01421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
400 Bakr NM, Awad A, Moustafa EA, El-Gebaly AM. The association between interleukin-21 (rs2055979G/T) gene polymorphism and the risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus. J Cell Biochem 2019;120:18524-32. [PMID: 31237020 DOI: 10.1002/jcb.29174] [Reference Citation Analysis]
401 Kong F, Hu W, Zhou K, Wei X, Kou Y, You H, Zheng K, Tang R. Hepatitis B virus X protein promotes interleukin-7 receptor expression via NF-κB and Notch1 pathway to facilitate proliferation and migration of hepatitis B virus-related hepatoma cells. J Exp Clin Cancer Res 2016;35:172. [PMID: 27821177 DOI: 10.1186/s13046-016-0448-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
402 Gewaid H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, Abdel Shafy RN, Emara N, Hamdy SM, Gewaid M, Bahgat MM. Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate. J Med Virol 2018;90:545-58. [PMID: 29064582 DOI: 10.1002/jmv.24977] [Reference Citation Analysis]
403 Maepa MB, Ely A, Grayson W, Arbuthnot P. Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs. Mol Ther Nucleic Acids 2017;7:190-9. [PMID: 28624194 DOI: 10.1016/j.omtn.2017.04.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
404 Coppola N, Onorato L, Iodice V, Starace M, Minichini C, Farella N, Liorre G, Filippini P, Sagnelli E, de Stefano G. Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. Oncotarget. 2016;7:62706-62714. [PMID: 27486882 DOI: 10.18632/oncotarget.10909] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
405 Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K, Suzuki M, Morita S, Taguri M, Tanaka K. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. Hepatol Res. 2015;45:279-287. [PMID: 24802232 DOI: 10.1111/hepr.12354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
406 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 149] [Article Influence: 47.3] [Reference Citation Analysis]
407 Juric V, Ruffell B, Evason KJ, Hu J, Che L, Wang L, Chen X, Bishop JM. Monocytes promote liver carcinogenesis in an oncogene-specific manner. J Hepatol 2016;64:881-90. [PMID: 26639397 DOI: 10.1016/j.jhep.2015.11.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
408 Hong M, Bertoletti A. Tolerance and immunity to pathogens in early life: insights from HBV infection. Semin Immunopathol. 2017;39:643-652. [PMID: 28685270 DOI: 10.1007/s00281-017-0641-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
409 Li X, Diao W, Xue H, Wu F, Wang W, Jiang B, Bai J, Lian B, Feng W, Sun T, Yu W, Wu J, Qu M, Wang Y, Gao Z. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma. Cancer Lett 2020;489:163-73. [PMID: 32592729 DOI: 10.1016/j.canlet.2020.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
410 Massarweh NN, Davila JA, El-Serag HB, Duan Z, Temple S, May S, Sada YH, Anaya DA. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res 2016;200:552-9. [PMID: 26507276 DOI: 10.1016/j.jss.2015.09.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
411 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 580] [Article Influence: 165.3] [Reference Citation Analysis]
412 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
413 Ma W, Soliman AS, Anwar WA, Hablas A, El Din TB, Ramadan M, Seifeldin IA, Wilson ML. Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt's hepatocellular cancer epidemic: simulation of alternatives. BMJ Glob Health 2018;3:e000572. [PMID: 29707244 DOI: 10.1136/bmjgh-2017-000572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
414 Chen SP, Zhang LS, Fu BS, Zeng XC, Yi HM, Jiang N. Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival. Medicine (Baltimore) 2015;94:e423. [PMID: 25634174 DOI: 10.1097/MD.0000000000000423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
415 Nakatsuka K, Atsukawa M, Shimizu M, Takahashi H, Kawamoto C. Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol 2015;7:2590-6. [PMID: 26557951 DOI: 10.4254/wjh.v7.i25.2590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
416 Younossi ZM, Stepanova M, Saab S, Ahmed A, Lam B, Srishord M, Venkatesan C, Wai H, Henry L. The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. J Viral Hepat. 2015;Aug 20; Epub ahead of print. [PMID: 26289820 DOI: 10.1111/jvh.12449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
417 Hallager S, Ladelund S, Christensen PB, Kjær M, Thorup Roege B, Grønbæk KE, Belard E, Barfod TS, Madsen LG, Gerstoft J, Tarp B, Krarup HB, Weis N. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. Clin Epidemiol 2017;9:501-16. [PMID: 29123424 DOI: 10.2147/CLEP.S132072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
418 Yamazaki H, Tsuji K, Nagai K, Tomonari A, Matsui T, Kang J, Kodama Y, Sakurai Y, Maguchi H. Efficacy and long-term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma: RFA in the elderly with HCC. Hepatol Res 2014;44:1095-101. [DOI: 10.1111/hepr.12233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
419 Di Martino M, Saba L, Bosco S, Rossi M, Miles KA, Di Miscio R, Lombardo CV, Tamponi E, Piga M, Catalano C. Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings. Eur Radiol 2014;24:1446-54. [DOI: 10.1007/s00330-014-3173-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
420 Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol. 2016;51:473-486. [PMID: 26553052 DOI: 10.1007/s00535-015-1126-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
421 Takaki H, Yamakado K, Tsurusaki M, Yasumoto T, Baba Y, Narimatsu Y, Shimohira M, Yamaguchi M, Matsuo K, Inaba Y. Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study. Int J Clin Oncol. 2015;20:745-754. [PMID: 25432660 DOI: 10.1007/s10147-014-0773-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
422 Yang W, Zhao J, Wang Y, Xu H, Wu Z, Hu Y, Jiang K, Shen P, Ma C, Guan Z, Zhang Y, Ma J, Shang N, Yan G, Wang Z, Dai G. In vivo inhibitory activity of andrographolide derivative ADN-9 against liver cancer and its mechanisms involved in inhibition of tumor angiogenesis. Toxicology and Applied Pharmacology 2017;327:1-12. [DOI: 10.1016/j.taap.2017.04.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
423 Yuan YH, Zhou CF, Yuan J, Liu L, Guo XR, Wang XL, Ding Y, Wang XN, Li DS, Tu HJ. NaHCO3 enhances the antitumor activities of cytokine-induced killer cells against hepatocellular carcinoma HepG2 cells. Oncol Lett 2016;12:3167-74. [PMID: 27899977 DOI: 10.3892/ol.2016.5112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
424 Tovoli F, Ferri S, Piscaglia F. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Curr Pharm Des 2020;26:3909-14. [PMID: 32348210 DOI: 10.2174/1381612826666200429093648] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
425 Hwang S, Jo M, Hong JE, Park CO, Lee CG, Yun M, Rhee KJ. Zerumbone Suppresses Enterotoxigenic Bacteroides fragilis Infection-Induced Colonic Inflammation through Inhibition of NF-κΒ. Int J Mol Sci 2019;20:E4560. [PMID: 31540059 DOI: 10.3390/ijms20184560] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
426 Lohmann V, Bartenschlager R. On the History of Hepatitis C Virus Cell Culture Systems: Miniperspective. J Med Chem 2014;57:1627-42. [DOI: 10.1021/jm401401n] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
427 Xi S, Peng Y, Minuk GY, Shi M, Fu B, Yang J, Li Q, Gong Y, Yue L, Li L, Guo J, Peng Y, Wang Y. The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy. Journal of Ethnopharmacology 2016;190:1-12. [DOI: 10.1016/j.jep.2016.05.055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
428 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
429 Pomo JM, Taylor RM, Gullapalli RR. Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics. Cancer Cell Int 2016;16:44. [PMID: 27303212 DOI: 10.1186/s12935-016-0318-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
430 Gyedu A, Shrauner WR, Kingham TP. No patients to resect or transplant: an analysis of patients with hepatocellular carcinoma admitted to a major African referral hospital. World J Surg 2015;39:231-6. [PMID: 25167899 DOI: 10.1007/s00268-014-2762-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
431 El-Maksoud MA, Habeeb MR, Ghazy HF, Nomir MM, Elalfy H, Abed S, Zaki MES. Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2019;31:716-722. [PMID: 30870221 DOI: 10.1097/meg.0000000000001388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
432 Augello G, Balasus D, Fusilli C, Mazza T, Emma MR, Giannitrapani L, Agliastro R, Cervello M, Montalto G. Association Between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample. OMICS 2018;22:274-82. [PMID: 29584564 DOI: 10.1089/omi.2017.0215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
433 Hsieh WY, Chen PH, Lin IY, Su CW, Chao Y, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC. The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Sci Rep 2017;7:42577. [PMID: 28209963 DOI: 10.1038/srep42577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
434 Tong MJ, Huynh TT, Siripongsakun S. Familial clustering of hepatocellular carcinoma in HBsAg-positive patients in the United States. Hepatol Int 2013;7:1019-29. [PMID: 26202031 DOI: 10.1007/s12072-013-9447-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
435 Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol 2019;31:743-8. [PMID: 31008808 DOI: 10.1097/MEG.0000000000001419] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
436 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 198] [Article Influence: 80.7] [Reference Citation Analysis]
437 Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim SJ, Paik SW, Park CK, Yoo BC. Outcomes after curative hepatectomy in patients with non-B non-C hepatocellular carcinoma and hepatitis B virus hepatocellular carcinoma from non-cirrhotic liver. J Surg Oncol 2014;110:976-81. [PMID: 25171344 DOI: 10.1002/jso.23772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
438 Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol 2013;19:8831-49. [PMID: 24379606 DOI: 10.3748/wjg.v19.i47.8831] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
439 Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2012;2:e001313. [PMID: 23089208 DOI: 10.1136/bmjopen-2012-001313] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
440 Alannan M, Fayyad-Kazan H, Trézéguet V, Merched A. Targeting Lipid Metabolism in Liver Cancer. Biochemistry 2020;59:3951-64. [PMID: 32930581 DOI: 10.1021/acs.biochem.0c00477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
441 Wu D, Jiang H, Yu H, Xu D, Liang J, Jin J. Significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma: a meta-analysis. Tumour Biol 2013;34:3865-9. [PMID: 23873110 DOI: 10.1007/s13277-013-0973-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
442 Yu CL, Weng MS, Chen WC, Chien KT, Chi CW, Chung CH, Huang CW, Wang PC, Chen CC, Tsai AC, Liu SC, Wang SW. Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway. Int J Mol Sci 2021;22:2930. [PMID: 33805784 DOI: 10.3390/ijms22062930] [Reference Citation Analysis]
443 Wake T, Tateishi R, Fukumoto T, Nakagomi R, Kinoshita MN, Nakatsuka T, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Fujinaga H, Asaoka Y, Tanaka Y, Otsuka M, Koike K. Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. PLoS One 2020;15:e0231836. [PMID: 32310974 DOI: 10.1371/journal.pone.0231836] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
444 Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S, Lu J, Zhao S, Qin L, Qin L, Chen X. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Oncotarget 2017;8:24785-96. [PMID: 28445973 DOI: 10.18632/oncotarget.15806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
445 Elpek GO. Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update. World J Clin Cases 2021;9:4890-917. [PMID: 34307543 DOI: 10.12998/wjcc.v9.i19.4890] [Reference Citation Analysis]
446 Wang W, Pan Q, Fuhler GM, Smits R, Peppelenbosch MP. Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol 2017;52:419-31. [PMID: 28035485 DOI: 10.1007/s00535-016-1299-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
447 Hartwell HJ, Petrosky KY, Fox JG, Horseman ND, Rogers AB. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice. Proc Natl Acad Sci USA. 2014;111:11455-11460. [PMID: 25049387 DOI: 10.1073/pnas.1404267111] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
448 Kunanopparat A, Issara-Amphorn J, Leelahavanichkul A, Sanpavat A, Patumraj S, Tangkijvanich P, Palaga T, Hirankarn N. Delta-like ligand 4 in hepatocellular carcinoma intrinsically promotes tumour growth and suppresses hepatitis B virus replication. World J Gastroenterol 2018;24:3861-70. [PMID: 30228780 DOI: 10.3748/wjg.v24.i34.3861] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
449 Shu Y, Lu Y, Pang X, Zheng W, Huang Y, Li J, Ji J, Zhang C, Shen P. Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4. Oncotarget 2016;7:76984-94. [PMID: 27769068 DOI: 10.18632/oncotarget.12764] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
450 Steels A, Bertier L, Gettemans J. Use, Applications and Mechanisms of Intracellular Actions of Camelid VHHs. In: Böldicke T, editor. Antibody Engineering. InTech; 2018. [DOI: 10.5772/intechopen.70495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
451 Badawy AA, El-hindawi A, Hammam O, Moussa M, Gabal S, Said N. Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus-induced hepatocarcinogenesis. APMIS 2015;123:823-31. [DOI: 10.1111/apm.12431] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
452 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462-3471. [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
453 Ferrasi AC, Fernandez GJ, Grotto RMT, Silva GF, Goncalves J, Costa MC, Enguita FJ, Pardini MIMC. New LncRNAs in Chronic Hepatitis C progression: from fibrosis to hepatocellular carcinoma. Sci Rep 2020;10:9886. [PMID: 32555359 DOI: 10.1038/s41598-020-66881-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
454 Huang P, Zhu LG, Zhu YF, Yue M, Su J, Zhu FC, Yang HT, Zhang Y, Shen HB, Yu RB, Zhai XJ, Peng ZH. Seroepidemiology of hepatitis B virus infection and impact of vaccination. World J Gastroenterol 2015;21:7842-50. [PMID: 26167084 DOI: 10.3748/wjg.v21.i25.7842] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
455 Wilkinson PD, Duncan AW. Differential Roles for Diploid and Polyploid Hepatocytes in Acute and Chronic Liver Injury. Semin Liver Dis 2021;41:42-9. [PMID: 33764484 DOI: 10.1055/s-0040-1719175] [Reference Citation Analysis]
456 Dzubow R, Fields C, Ginsberg G, Sandy M, Mabson M, Foos B. Comparison of carcinogenic potency across life stages: implications for the assessment of transplacental cancer risk. J Toxicol Environ Health A 2019;82:769-87. [PMID: 31402766 DOI: 10.1080/15287394.2019.1650860] [Reference Citation Analysis]
457 Zhang Q, Xu X, Wu M, Qin T, Wu S, Liu H. MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis. Front Oncol 2020;10:562019. [PMID: 33542895 DOI: 10.3389/fonc.2020.562019] [Reference Citation Analysis]
458 Ho CH, Chuang HC, Wu IC, Tsai HW, Lin YJ, Sun HY, Young KC, Chiu YC, Cheng PN, Liu WC, Tan TH, Chang TT. Prediction of early hepatocellular carcinoma recurrence using germinal center kinase-like kinase. Oncotarget 2016;7:49765-76. [PMID: 27343552 DOI: 10.18632/oncotarget.10176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
459 Zhang J, Zhu Y, Hu L, Yan F, Chen J. miR-494 induces EndMT and promotes the development of HCC (Hepatocellular Carcinoma) by targeting SIRT3/TGF-β/SMAD signaling pathway. Sci Rep 2019;9:7213. [PMID: 31076630 DOI: 10.1038/s41598-019-43731-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
460 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1632-1651. [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 113] [Cited by in F6Publishing: 97] [Article Influence: 18.8] [Reference Citation Analysis]
461 Liu TF, McCall CE. Deacetylation by SIRT1 Reprograms Inflammation and Cancer. Genes Cancer. 2013;4:135-147. [PMID: 24020005 DOI: 10.1177/1947601913476948] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
462 Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, Parikh ND, Browning T, Singal AG. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77. [PMID: 27862091 DOI: 10.1111/apt.13841] [Cited by in Crossref: 117] [Cited by in F6Publishing: 97] [Article Influence: 23.4] [Reference Citation Analysis]
463 Lee KC, Cheng YT, Lin CY, Kuo CJ, Chien RN, Yeh CT, Chang ML. Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13-year prospective cohort study. Eur J Clin Invest 2020;50:e13189. [PMID: 31782138 DOI: 10.1111/eci.13189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
464 Tavakkoli M, Ferrando SJ, Rabkin J, Marks K, Talal AH. Depression and fatigue in chronic hepatitis C patients with and without HIV co-infection. Psychosomatics. 2013;54:466-471. [PMID: 23756122 DOI: 10.1016/j.psym.2013.02.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
465 Sasaki R, Devhare P, Ray RB, Ray R. Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model. Hepatology 2017;66:1766-78. [PMID: 28664988 DOI: 10.1002/hep.29346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
466 Wang W, Xu L, Liu P, Jairam K, Yin Y, Chen K, Sprengers D, Peppelenbosch MP, Pan Q, Smits R. Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of β-Catenin Signaling. Neoplasia 2016;18:711-23. [PMID: 27851986 DOI: 10.1016/j.neo.2016.10.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
467 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 317] [Article Influence: 121.7] [Reference Citation Analysis]
468 Lin SY, Lin CL, Chen WS, Lin CC, Lin CH, Hsu WH, Hsu CY, Kao CH. Association Between Alcoholic Cirrhosis and Hemorrhagic Stroke: A Nationwide Population-based Study. Alcohol Alcohol 2019;54:302-9. [PMID: 30957143 DOI: 10.1093/alcalc/agz025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
469 Sam SS, Steinmetz HB, Tsongalis GJ, Tafe LJ, Lefferts JA. Validation of a solid-phase electrochemical array for genotyping hepatitis C virus. Exp Mol Pathol. 2013;95:18-22. [PMID: 23583628 DOI: 10.1016/j.yexmp.2013.04.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
470 Liu Y, Kuang S, Zheng J, Zheng J, Jin H, Chen S, Jian Z. Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis. Tumour Biol 2014;35:961-5. [PMID: 24061636 DOI: 10.1007/s13277-013-1128-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
471 Kudo M, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol 2016;51:1150-60. [PMID: 27106231 DOI: 10.1007/s00535-016-1204-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
472 Czauderna C, Castven D, Mahn FL, Marquardt JU. Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer-from Tumor Development to Therapeutic Implications. Cancers (Basel) 2019;11:E1053. [PMID: 31349670 DOI: 10.3390/cancers11081053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
473 El-Gazzaz G, Sourianarayanane A, Menon KVN, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. Hepatobiliary & Pancreatic Diseases International. 2013;12:34-41. [PMID: 23392796 DOI: 10.1016/s1499-3872(13)60003-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
474 Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939-946. [PMID: 24950276 DOI: 10.1097/sla.0000000000000747] [Cited by in Crossref: 128] [Cited by in F6Publishing: 60] [Article Influence: 21.3] [Reference Citation Analysis]
475 Ohkoshi S, Yano M, Matsuda Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol 2015;21:12150-6. [PMID: 26576099 DOI: 10.3748/wjg.v21.i42.12150] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
476 Xu Y, He X, Deng J, Xiong L, Li Y, Zhang X, Chen W, Liu X, Xu X. Comprehensive Analysis of the Immune Infiltrates and PD-L1 of m6A RNA Methylation Regulators in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:681745. [PMID: 34277622 DOI: 10.3389/fcell.2021.681745] [Reference Citation Analysis]
477 Pereyra D, Offensperger F, Klinglmueller F, Haegele S, Oehlberger L, Gruenberger T, Brostjan C, Starlinger P. Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity. PLoS One 2017;12:e0175359. [PMID: 28406940 DOI: 10.1371/journal.pone.0175359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
478 Osório FMF, Lauar GM, Lima AS, Vidigal PVT, Ferrari TCA, Couto CA. EPIDEMIOLOGICAL ASPECTS OF HEPATOCELLULAR CARCINOMA IN A REFERRAL CENTER OF MINAS GERAIS, BRAZIL. Arq Gastroenterol 2013;50:97-100. [DOI: 10.1590/s0004-28032013000200015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
479 Sperle I, Steffen G, Leendertz SA, Sarma N, Beermann S, Thamm R, Simeonova Y, Cornberg M, Wedemeyer H, Bremer V, Zimmermann R, Dudareva S. Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. Front Public Health 2020;8:424. [PMID: 33014960 DOI: 10.3389/fpubh.2020.00424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
480 Singaravelu R, Delcorde J, Lyn RK, Steenbergen RH, Jones DM, Tyrrell DL, Russell RS, Pezacki JP. Investigating the antiviral role of cell death-inducing DFF45-like effector B in HCV replication. FEBS J. 2014;281:3751-3765. [PMID: 24980280 DOI: 10.1111/febs.12901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
481 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 14.0] [Reference Citation Analysis]
482 Mah Y, Liu C, Chen C, Tseng T, Liu C, Chen P, Chen D, Kao J. Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. Journal of the Formosan Medical Association 2016;115:953-60. [DOI: 10.1016/j.jfma.2016.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
483 Mansberg K, Kull K, Salupere R, Prükk T, Margus B, Kariis T, Remmel T, Suurmaa K, Ott K, Jaago K, Šmidt J. A Population-Based Surveillance Study on the Epidemiology of Hepatitis C in Estonia. Medicina (Kaunas) 2018;54:E9. [PMID: 30344240 DOI: 10.3390/medicina54010009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
484 Lok AS, Pawlotsky JM. Viral hepatitis at a crossroad. Gastroenterology 2012;142:1261-3. [PMID: 22537431 DOI: 10.1053/j.gastro.2012.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
485 Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med 2019;171:318-27. [PMID: 31426090 DOI: 10.7326/M18-2753] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
486 Xiong H, Ni Z, He J, Jiang S, Li X, He J, Gong W, Zheng L, Chen S, Li B, Zhang N, Lyu X, Huang G, Chen B, Zhang Y, He F. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017;36:3528-3540. [PMID: 28166203 DOI: 10.1038/onc.2016.521] [Cited by in Crossref: 182] [Cited by in F6Publishing: 191] [Article Influence: 45.5] [Reference Citation Analysis]
487 Shubin AV, Demidyuk IV, Komissarov AA, Rafieva LM, Kostrov SV. Cytoplasmic vacuolization in cell death and survival. Oncotarget 2016;7:55863-89. [PMID: 27331412 DOI: 10.18632/oncotarget.10150] [Cited by in Crossref: 108] [Cited by in F6Publishing: 82] [Article Influence: 36.0] [Reference Citation Analysis]
488 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
489 Wu T, Chu C, Chang Liao H, Lin S, Ho T, Lin M, Lin HH, Wang L. HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy. Genes Immun 2014;15:47-53. [DOI: 10.1038/gene.2013.62] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
490 Lamontagne J, Mell JC, Bouchard MJ. Transcriptome-Wide Analysis of Hepatitis B Virus-Mediated Changes to Normal Hepatocyte Gene Expression. PLoS Pathog 2016;12:e1005438. [PMID: 26891448 DOI: 10.1371/journal.ppat.1005438] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
491 Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y, Ren Y, Liang Z, Zhou P, Zhang Y, Bao Y, Li Y. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer 2020;8:e001748. [PMID: 33323464 DOI: 10.1136/jitc-2020-001748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
492 Yang Y, Gao J, Li HL, Zheng W, Yang G, Zhang W, Ma X, Tan YT, Rothman N, Gao YT. Dose-response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and women. Int J Cancer. 2016;139:355-362. [PMID: 26990915 DOI: 10.1002/ijc.30086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
493 Cucchetti A, Trevisani F, Bucci L, Ravaioli M, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Maida M, Felder M, Morisco F, Gasbarrini A, Gemini S, Foschi FG, Missale G, Masotto A, Affronti A, Bernardi M, Pinna AD; the Italian Liver Cancer (ITA.LI.CA) group. Years of life that could be saved from prevention of hepatocellular carcinoma. Aliment Pharmacol Ther 2016;43:814-24. [DOI: 10.1111/apt.13554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
494 Mahale P, Kaseb AO, Hassan MM, Torres HA. Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. Dig Liver Dis 2015;47:348-9. [PMID: 25563811 DOI: 10.1016/j.dld.2014.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
495 An Y, Zhao J, Zhang Y, Wu W, Hu J, Hao H, Qiao Y, Tao Y, An L. Rosmarinic Acid Induces Proliferation Suppression of Hepatoma Cells Associated with NF-κB Signaling Pathway. Asian Pac J Cancer Prev 2021;22:1623-32. [PMID: 34048194 DOI: 10.31557/APJCP.2021.22.5.1623] [Reference Citation Analysis]
496 Kurahashi T, Yoshida Y, Ogura S, Egawa M, Furuta K, Hikita H, Kodama T, Sakamori R, Kiso S, Kamada Y, Wang IC, Eguchi H, Morii E, Doki Y, Mori M, Kalinichenko VV, Tatsumi T, Takehara T. Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice. Cell Mol Gastroenterol Hepatol 2020;9:425-46. [PMID: 31669262 DOI: 10.1016/j.jcmgh.2019.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
497 Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014;15:2609-22. [PMID: 25347030 DOI: 10.1517/14656566.2014.972364] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
498 Pang Q, Bi JB, Wang ZX, Xu XS, Qu K, Miao RC, Chen W, Zhou YY, Liu C. Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. Onco Targets Ther 2016;9:2099-109. [PMID: 27110127 DOI: 10.2147/OTT.S101465] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
499 Datta S, Dasgupta D, Ghosh A, Ghosh S, Manna A, Datta S, Chatterjee M, Chowdhury A, Banerjee S. Oncogenic potential of hepatitis B virus subgenotype D1 surpasses D3: significance in the development of hepatocellular carcinoma. Carcinogenesis 2018;39:283-92. [PMID: 29228221 DOI: 10.1093/carcin/bgx145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
500 Kinoshita A, Onoda H, Ueda K, Imai N, Iwaku A, Tanaka K, Fushiya N, Koike K, Nishino H, Tajiri H. Clinical characteristics and survival outcomes of super-elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatol Res 2016;46:E5-E14. [PMID: 25753133 DOI: 10.1111/hepr.12514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
501 Hobeika C, Fuks D, Cauchy F, Goumard C, Soubrane O, Gayet B, Salamé E, Cherqui D, Vibert E, Scatton O, Nomi T, Oudafal N, Kawai T, Komatsu S, Okumura S, Petrucciani N, Laurent A, Bucur P, Barbier L, Trechot B, Nunèz J, Tedeschi M, Allard MA, Golse N, Ciacio O, Pittau G, Cunha AS, Adam R, Laurent C, Chiche L, Leourier P, Rebibo L, Regimbeau JM, Ferre L, Souche FR, Chauvat J, Fabre JM, Jehaes F, Mohkam K, Lesurtel M, Ducerf C, Mabrut JY, Hor T, Paye F, Balladur P, Suc B, Muscari F, Millet G, El Amrani M, Ratajczak C, Lecolle K, Boleslawski E, Truant S, Pruvot FR, Kianmanesh AR, Codjia T, Schwarz L, Girard E, Abba J, Letoublon C, Chirica M, Carmelo A, VanBrugghe C, Cherkaoui Z, Unterteiner X, Memeo R, Pessaux P, Buc E, Lermite E, Barbieux J, Bougard M, Marchese U, Ewald J, Turini O, Thobie A, Menahem B, Mulliri A, Lubrano J, Zemour J, Fagot H, Passot G, Gregoire E, Hardwigsen J, le Treut YP, Patrice D; AFC-LLR-2018 study group. Impact of cirrhosis in patients undergoing laparoscopic liver resection in a nationwide multicentre survey. Br J Surg 2020;107:268-77. [PMID: 31916594 DOI: 10.1002/bjs.11406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
502 Ngamruengphong S, Patel T. Molecular evolution of genetic susceptibility to hepatocellular carcinoma. Dig Dis Sci 2014;59:986-91. [PMID: 24357186 DOI: 10.1007/s10620-013-2984-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
503 Abbas A, Medvedev S, Shores N, Bazzano L, Dehal A, Hutchings J, Balart L. Epidemiology of metastatic hepatocellular carcinoma, a nationwide perspective. Dig Dis Sci 2014;59:2813-20. [PMID: 24903653 DOI: 10.1007/s10620-014-3229-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
504 Li Z, Hao D, Jiao D, Zhang W, Han X. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures. Acad Radiol 2020:S1076-6332(20)30518-3. [PMID: 33060007 DOI: 10.1016/j.acra.2020.08.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
505 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
506 [DOI: 10.1101/568147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
507 Kennedy LB, Li Z, Savani BN, Ljungman P. Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2017;23:1614-21. [DOI: 10.1016/j.bbmt.2017.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
508 Li D, von Schaewen M, Wang X, Tao W, Zhang Y, Li L, Heller B, Hrebikova G, Deng Q, Ploss A, Zhong J, Huang Z. Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. J Virol 2016;90:10486-98. [PMID: 27630242 DOI: 10.1128/JVI.01462-16] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
509 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
510 Meng L, Zhou Y, Ju S, Han J, Song C, Kong J, Wu Y, Lu S, Xu J, Yuan W, Zhang E, Wang C, Hu Z, Gu Y, Luo R, Wang X. A cis-eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. Cancer Med 2019;8:6476-84. [PMID: 31489978 DOI: 10.1002/cam4.2487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
511 Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014;46:1267-1273. [PMID: 25362482 DOI: 10.1038/ng.3126] [Cited by in Crossref: 418] [Cited by in F6Publishing: 375] [Article Influence: 59.7] [Reference Citation Analysis]
512 Roderburg C, Tacke F, Trautwein C. Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. Visc Med. 2016;32:121-126. [PMID: 27413730 DOI: 10.1159/000444990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
513 Chan MY, She WH, Dai WC, Tsang SHY, Chok KSH, Chan ACY, Fung J, Lo CM, Cheung TT. Prognostic value of preoperative alpha-fetoprotein (AFP) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in Hong Kong. Transl Gastroenterol Hepatol 2019;4:52. [PMID: 31463411 DOI: 10.21037/tgh.2019.06.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
514 Jain S, Su YH, Su YP, McCloud S, Xue R, Lee TJ, Lin SC, Lin SY, Song W, Steffen JD, Hu CT. Characterization of the hepatitis B virus DNA detected in urine of chronic hepatitis B patients. BMC Gastroenterol 2018;18:40. [PMID: 29548283 DOI: 10.1186/s12876-018-0767-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
515 Woldegiorgis AE, Erku W, Medhin G, Berhe N, Legesse M. Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia. PLoS One 2019;14:e0226890. [PMID: 31887192 DOI: 10.1371/journal.pone.0226890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
516 Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat 2018;25:945-51. [DOI: 10.1111/jvh.12886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
517 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
518 Kaufmann S, Horger T, Oelker A, Beck S, Schulze M, Nikolaou K, Ketelsen D, Horger M. Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation. Eur J Radiol 2015;84:2548-54. [PMID: 26428842 DOI: 10.1016/j.ejrad.2015.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
519 Si T, Chen Y, Ma D, Gong X, Yang K, Guan R, Peng C. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials. Scand J Gastroenterol. 2016;51:1512-1519. [PMID: 27598831 DOI: 10.1080/00365521.2016.1216588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
520 Ahmed W, Mofed D, Zekri AR, El-Sayed N, Rahouma M, Sabet S. Antioxidant activity and apoptotic induction as mechanisms of action of Withania somnifera (Ashwagandha) against a hepatocellular carcinoma cell line. J Int Med Res 2018;46:1358-69. [PMID: 29392963 DOI: 10.1177/0300060517752022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
521 Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma: An Aggressive Subtype of Hepatocellular Carcinoma. American Journal of Surgical Pathology 2019;43:943-8. [DOI: 10.1097/pas.0000000000001289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
522 Ali M, Yopp A, Gopal P, Beg MS, Zhu H, Lee W, Singal AG. A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2016;14:295-300. [PMID: 26305067 DOI: 10.1016/j.cgh.2015.08.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
523 Honda K, Seike M, Murakami K. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol 2015;7:2404-10. [PMID: 26464756 DOI: 10.4254/wjh.v7.i22.2404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
524 Wang XY, Fang AP, Chen PY, Liao GC, Zhang YJ, Shivappa N, Hébert JR, Chen YM, Zhu HL. High dietary inflammatory index scores are associated with an elevated risk of hepatocellular carcinoma in a case-control study. Food Funct 2018;9:5832-42. [PMID: 30357201 DOI: 10.1039/c8fo01190g] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
525 Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH. Liver resection in elderly patients with hepatocellular carcinoma: age does matter. Updates Surg 2021;73:1371-80. [PMID: 33687694 DOI: 10.1007/s13304-021-01021-7] [Reference Citation Analysis]
526 Xu H, He C, Liu Y, Jiang J, Ma T. Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif Cells Nanomed Biotechnol 2018;46:1902-7. [PMID: 29081246 DOI: 10.1080/21691401.2017.1396222] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
527 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 102] [Cited by in F6Publishing: 88] [Article Influence: 51.0] [Reference Citation Analysis]
528 Sun S, Nakashima K, Ito M, Li Y, Chida T, Takahashi H, Watashi K, Sawasaki T, Wakita T, Suzuki T. Involvement of PUF60 in Transcriptional and Post-transcriptional Regulation of Hepatitis B Virus Pregenomic RNA Expression. Sci Rep 2017;7:12874. [PMID: 28993636 DOI: 10.1038/s41598-017-12497-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
529 Wen X, Reynolds L, Mulik RS, Kim SY, Van Treuren T, Nguyen LH, Zhu H, Corbin IR. Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. Gastroenterology 2016;150:488-98. [PMID: 26484708 DOI: 10.1053/j.gastro.2015.10.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
530 Huang J, Liu FC, Li L, Zhou WP, Jiang BG, Pan ZY. Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. Cancer Med 2020;9:2791-802. [PMID: 32096346 DOI: 10.1002/cam4.2944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
531 Zona L, Tawar RG, Zeisel MB, Xiao F, Schuster C, Lupberger J, Baumert TF. CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses 2014;6:875-92. [PMID: 24553110 DOI: 10.3390/v6020875] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
532 Cannalire R, Barreca ML, Manfroni G, Cecchetti V. A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. J Med Chem 2016;59:16-41. [PMID: 26241789 DOI: 10.1021/acs.jmedchem.5b00825] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
533 Shimada S, Kamiyama T, Orimo T, Nagatsu A, Asahi Y, Sakamoto Y, Kamachi H, Taketomi A. Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy. World J Surg Oncol 2020;18:122. [PMID: 32522259 DOI: 10.1186/s12957-020-01899-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
534 Alaarg A, Pérez-Medina C, Metselaar JM, Nahrendorf M, Fayad ZA, Storm G, Mulder WJM. Applying nanomedicine in maladaptive inflammation and angiogenesis. Adv Drug Deliv Rev 2017;119:143-58. [PMID: 28506745 DOI: 10.1016/j.addr.2017.05.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
535 Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016. Cancer Causes Control 2019;30:1377-88. [PMID: 31606852 DOI: 10.1007/s10552-019-01237-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
536 Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, Chen B, Chen P, Mao F, Yu Q. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;35:1467-1476. [PMID: 32180249 DOI: 10.1111/jgh.15036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
537 Galal G, Tammam H, Abdel Aal A, Fahmy N, Sheneef A, Ahmed N, Zaghloul A. Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders. Infect Drug Resist 2021;14:1921-30. [PMID: 34079302 DOI: 10.2147/IDR.S306879] [Reference Citation Analysis]
538 Idilman R, Demir M, Aladag M, Erol C, Cavus B, Iliaz R, Koklu H, Cakaloglu Y, Sahin M, Ersoz G, Koksal İ, Karasu Z, Ozgenel M, Turan İ, Gunduz F, Ataseven H, Akdogan M, Kiyici M, Koksal AS, Akhan S, Gunsar F, Tabak F, Kaymakoglu S, Akarca US; Early Access Program (EAP) Study Groupa. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. J Viral Hepat 2019;26:666-74. [PMID: 30740820 DOI: 10.1111/jvh.13075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
539 Ferrín G, Ranchal I, Llamoza C, Rodríguez-Perálvarez ML, Romero-Ruiz A, Aguilar-Melero P, López-Cillero P, Briceño J, Muntané J, Montero-Álvarez JL, De la Mata M. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE. Liver Int 2014;34:438-46. [PMID: 23944848 DOI: 10.1111/liv.12277] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
540 Sun J, Zhao Y, Qin L, Li K, Zhao Y, Sun H, Zhang T, Zhang Y. Metabolomic Profiles for HBV Related Hepatocellular Carcinoma Including Alpha-Fetoproteins Positive and Negative Subtypes. Front Oncol 2019;9:1069. [PMID: 31681602 DOI: 10.3389/fonc.2019.01069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
541 Xie Q, Fan F, Wei W, Liu Y, Xu Z, Zhai L, Qi Y, Ye B, Zhang Y, Basu S, Zhao Z, Wu J, Xu P. Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular carcinoma cells. Sci Rep 2017;7:41089. [PMID: 28112229 DOI: 10.1038/srep41089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
542 Vivero-escoto JL, Vadarevu H, Juneja R, Schrum LW, Benbow JH. Nanoparticle mediated silencing of tenascin C in hepatic stellate cells: effect on inflammatory gene expression and cell migration. J Mater Chem B 2019;7:7396-405. [DOI: 10.1039/c9tb01845j] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
543 Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;12:26-32. [PMID: 29541276 DOI: 10.2174/1874357901812010026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 28.0] [Reference Citation Analysis]
544 Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci 2019;76:4203-19. [PMID: 31300868 DOI: 10.1007/s00018-019-03215-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
545 White DL, Kanwal F, Jiao L, El-serag HB. Epidemiology of Hepatocellular Carcinoma. In: Carr BI, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2016. pp. 3-24. [DOI: 10.1007/978-3-319-34214-6_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
546 Khlaiphuengsin A, Chuaypen N, Sodsai P, Buranapraditkun S, Boonpiyathad T, Hirankarn N, Tangkijvanich P. Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2020;26:2645-56. [PMID: 32523317 DOI: 10.3748/wjg.v26.i20.2645] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
547 Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109:542-553. [PMID: 24513805 DOI: 10.1038/ajg.2014.11] [Cited by in Crossref: 269] [Cited by in F6Publishing: 229] [Article Influence: 38.4] [Reference Citation Analysis]
548 Noureddin M, Wright EC, Alter HJ, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner DE, Liang TJ. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58:1548-1557. [PMID: 23703931 DOI: 10.1002/hep.26506] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
549 Meier A, Yopp A, Mok H, Kandunoori P, Tiro J, Singal AG. Role functioning is associated with survival in patients with hepatocellular carcinoma. Qual Life Res 2015;24:1669-75. [PMID: 25502092 DOI: 10.1007/s11136-014-0895-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
550 Crespo J, Cuadrado A, Perelló C, Cabezas J, Llerena S, Llorca J, Cedillo S, Llop E, Escudero MD, Hernández Conde M, Puchades L, Redondo C, Fortea JI, Gil de Miguel A, Serra MA, Lazarus JV, Calleja JL. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. J Viral Hepat 2020;27:360-70. [PMID: 31755634 DOI: 10.1111/jvh.13238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
551 An P, Zeng Z, Winkler CA. The Loss-of-Function S267F Variant in HBV Receptor NTCP Reduces Human Risk for HBV Infection and Disease Progression. J Infect Dis 2018;218:1404-10. [PMID: 29905807 DOI: 10.1093/infdis/jiy355] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
552 Matthai SM, Ramakrishna B. Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association. Indian J Med Res 2015;142:391-8. [PMID: 26609030 DOI: 10.4103/0971-5916.169195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
553 Tan ZM, Sun BC. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol. 2013;19:8895-8901. [PMID: 24379613 DOI: 10.3748/wjg.v19.i47.8895] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
554 Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res. 2015;45:128-141. [PMID: 25040738 DOI: 10.1111/hepr.12386] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
555 Firl DJ, Kimura S, Mcvey J, Hashimoto K, Yeh H, Miller CM, Markmann JF, Sasaki K, Aucejo FN. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology 2018;68:1448-58. [DOI: 10.1002/hep.29907] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
556 Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Journal of Hepatology 2016;64:S117-31. [DOI: 10.1016/j.jhep.2016.02.016] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 24.0] [Reference Citation Analysis]
557 Naseer M, Hadi S, Syed A, Safdari A, Tahan V. Exosomes: A new frontier under the spotlight for diagnosis and treatment of gastrointestinal diseases. WJMA 2021;9:12-28. [DOI: 10.13105/wjma.v9.i1.12] [Reference Citation Analysis]
558 Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191-199. [PMID: 25142309 DOI: 10.1002/hep.27388] [Cited by in Crossref: 311] [Cited by in F6Publishing: 281] [Article Influence: 44.4] [Reference Citation Analysis]
559 Chen S, Peng Z, Xiao H, Lin M, Chen Z, Jiang C, Hu W, Xie X, Liu L, Peng B, Kuang M. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. Int J Hyperthermia 2018;34:1029-37. [PMID: 28974113 DOI: 10.1080/02656736.2017.1387941] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
560 Schweitzer CJ, Liang TJ. Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol 2013;3:501-7. [PMID: 23835049 DOI: 10.1016/j.coviro.2013.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
561 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016;22:8271-8282. [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
562 Wang S, Cui S, Zhao W, Qian Z, Liu H, Chen Y, Lv F, Ding HG. Screening and bioinformatics analysis of circular RNA expression profiles in hepatitis B-related hepatocellular carcinoma. Cancer Biomark. 2018;22:631-640. [PMID: 29914004 DOI: 10.3233/cbm-170910] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
563 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
564 Vedham V, Verma M, Mahabir S. Early-life exposures to infectious agents and later cancer development. Cancer Med 2015;4:1908-22. [PMID: 26377256 DOI: 10.1002/cam4.538] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
565 Zhang D, Liu H, Lin J, Ye D. Hepatitis B Virus Infection Dampens CtIP Expression in Hepatoma Cell. J Cancer 2018;9:1182-7. [PMID: 29675099 DOI: 10.7150/jca.23649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
566 Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation 2020;104:2087-96. [PMID: 31978002 DOI: 10.1097/TP.0000000000003115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
567 Vinciguerra M, Mazzoccoli G, Piccoli C, Tataranni T, Andriulli A, Pazienza V. Exploitation of host clock gene machinery by hepatitis viruses B and C. World J Gastroenterol 2013;19:8902-9. [PMID: 24379614 DOI: 10.3748/wjg.v19.i47.8902] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
568 Solis JG, Enciso López ES, Bautista Santos A, Anda Garay JC, Calixto Rodríguez JL, Moreno Alcántar R, Montiel López L. Effect of Direct Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C. Arch Med Res 2021:S0188-4409(21)00115-6. [PMID: 33972118 DOI: 10.1016/j.arcmed.2021.04.009] [Reference Citation Analysis]
569 Zhang Y, Xu X, Chen Z, Zhao Z. Association of FHIT expression and FHIT gene hypermethylation with liver cancer risk: a PRISMA-compliant meta-analysis. Onco Targets Ther 2017;10:3083-93. [PMID: 28790842 DOI: 10.2147/OTT.S138036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
570 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
571 Liu J, Chen S, Zou Z, Tan D, Liu X, Wang X. Pathological Pattern of Intrahepatic HBV in HCC is Phenocopied by PDX-Derived Mice: a Novel Model for Antiviral Treatment. Transl Oncol 2019;12:1138-46. [PMID: 31202090 DOI: 10.1016/j.tranon.2019.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
572 Liu J, Xu W, Zhu A, Kang H, Cao Y, Long F. Reusable optofluidic point-of-care testing platform with lyophilized specific antibody for fluorescence detection of cholylglycine in serum. Mikrochim Acta 2020;187:439. [PMID: 32653962 DOI: 10.1007/s00604-020-04424-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
573 Wu T, Chu C, Ho T, Chang Liao H, Lin S, Lin M, Lin HH, Wang L. Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents. Hum Genet 2013;132:1131-9. [DOI: 10.1007/s00439-013-1320-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
574 Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS. The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers. Diagnostics (Basel) 2015;5:546-63. [PMID: 26854170 DOI: 10.3390/diagnostics5040546] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
575 Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61:1397-1406. [PMID: 25157983 DOI: 10.1016/j.jhep.2014.08.025] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 13.4] [Reference Citation Analysis]
576 Liu C, Wu H, Mao Y, Chen W, Chen S. Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell Int 2021;21:254. [PMID: 33964930 DOI: 10.1186/s12935-021-01941-9] [Reference Citation Analysis]
577 You D, Cho YY, Lee H, Lee J, Yu SJ, Yoon J, Yoo YD, Kim YJ, Lee GY. Hepatitis B virus X protein induces size-selective membrane permeabilization through interaction with cardiolipin. Biochimica et Biophysica Acta (BBA) - Biomembranes 2019;1861:729-37. [DOI: 10.1016/j.bbamem.2019.01.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
578 Tawara S, Tatsumi T, Iio S, Kobayashi I, Shigekawa M, Hikita H, Sakamori R, Hiramatsu N, Miyoshi E, Takehara T. Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C. PLoS One 2016;11:e0151828. [PMID: 27002630 DOI: 10.1371/journal.pone.0151828] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
579 Chu YJ, Yang HI, Wu HC, Lee MH, Liu J, Wang LY, Lu SN, Jen CL, You SL, Santella RM, Chen CJ. Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. Eur J Cancer 2018;94:37-46. [PMID: 29533866 DOI: 10.1016/j.ejca.2018.02.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
580 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 31.0] [Reference Citation Analysis]
581 Zhang XF, Chao J, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Jiang SS, Chen CL, Zhang HX, Xia JC. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget 2015;6:40920-33. [PMID: 26506518 DOI: 10.18632/oncotarget.5712] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
582 Hoseini SS, Cheung NV. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett. 2017;399:44-52. [PMID: 28428075 DOI: 10.1016/j.canlet.2017.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
583 Vergara M, Bejarano G, Dalmau B, Gil M, Miquel M, Sanchez-Delgado J, Casas M, Puig J, Martinez-Bauer E, Dosal A, Lopez M, Moreno L, Valero O, Bella MR, Calvet X. Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2015;27:826-33. [PMID: 26043289 DOI: 10.1097/MEG.0000000000000346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
584 Trierweiler C, Hockenjos B, Zatloukal K, Thimme R, Blum HE, Wagner EF, Hasselblatt P. The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ 2016;23:576-82. [PMID: 26470729 DOI: 10.1038/cdd.2015.121] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
585 Liu XY, Ma LN, Yan TT, Lu ZH, Tang YY, Luo X, Ding XC. Combined detection of liver stiffness and C-reactive protein in patients with hepatitis B virus-related liver cirrhosis, with and without hepatocellular carcinoma. Mol Clin Oncol 2016;4:587-90. [PMID: 27073669 DOI: 10.3892/mco.2016.742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
586 Schweitzer CJ, Zhang F, Boyer A, Valdez K, Cam M, Liang TJ. N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly. J Virol 2018;92:e01166-17. [PMID: 29118118 DOI: 10.1128/JVI.01166-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
587 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
588 Hsu HT, Chi CW. Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:127-35. [PMID: 27508182 DOI: 10.2147/JHC.S48512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
589 Ji XW, Jiang Y, Wu H, Zhou P, Tan YT, Li HL, Zhang L, Zhao WS, Xia QH, Bray F, Xiang YB. Long-term liver cancer incidence and mortality trends in the Changning District of Shanghai, China. J Dig Dis 2020;21:230-6. [PMID: 32124559 DOI: 10.1111/1751-2980.12855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
590 Raksayot M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, Treeprasertsuk S, Poovorawan Y, Tanaka Y, Tangkijvanich P. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. J Gastroenterol 2019;54:427-36. [PMID: 30506232 DOI: 10.1007/s00535-018-01533-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
591 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Reference Citation Analysis]
592 Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA, Yopp AC, Singal AG. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019;17:551-559.e1. [PMID: 29859983 DOI: 10.1016/j.cgh.2018.05.039] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
593 Sulczewski FB, Liszbinski RB, Romão PRT, Rodrigues Junior LC. Nanoparticle vaccines against viral infections. Arch Virol 2018;163:2313-25. [PMID: 29728911 DOI: 10.1007/s00705-018-3856-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
594 Lin SY, Zhang A, Lian J, Wang J, Chang TT, Lin YJ, Song W, Su YH. Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma. Cells 2021;10:1294. [PMID: 34071075 DOI: 10.3390/cells10061294] [Reference Citation Analysis]
595 Tan W, Li Y, Lim SG, Tan TM. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol. 2014;20:5962-5972. [PMID: 24876719 DOI: 10.3748/wjg.v20.i20.5962] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 62] [Article Influence: 10.2] [Reference Citation Analysis]
596 Kim W, Lee S, Son Y, Ko C, Ryu WS. DDB1 Stimulates Viral Transcription of Hepatitis B Virus via HBx-Independent Mechanisms. J Virol 2016;90:9644-53. [PMID: 27535046 DOI: 10.1128/JVI.00977-16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
597 Fiorino S. HBV and HCV infection and pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2013;12:570-4. [PMID: 24322740 DOI: 10.1016/s1499-3872(13)60090-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
598 Li J, Li J, Bao Y, Pan K, Lin X, Liu X, Wang H, Xu Y, Luo X, Li H, Duan C. Low Frequency of Peripheral Lymphocyte in Chronic Hepatitis B Patients Predicts Poor Progression to Hepatocellular Carcinoma. J Clin Lab Anal 2016;30:208-15. [PMID: 25600684 DOI: 10.1002/jcla.21838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
599 Chiu AP, Tschida BR, Sham TT, Lo LH, Moriarity BS, Li XX, Lo RC, Hinton DE, Rowlands DK, Chan CO, Mok DKW, Largaespada DA, Warner N, Keng VW. HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism. Mol Cancer Res. 2019;17:1582-1593. [PMID: 30975706 DOI: 10.1158/1541-7786.mcr-18-1127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
600 Bhoori S, Mazzaferro V. Current challenges in liver transplantation for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:867-79. [DOI: 10.1016/j.bpg.2014.08.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
601 Tajiri K, Baba H, Kawai K, Minemura M, Yasumura S, Takahara T, Sugiyama T. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol. 2016;31:1291-1299. [PMID: 26729319 DOI: 10.1111/jgh.13287] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
602 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in Crossref: 205] [Cited by in F6Publishing: 194] [Article Influence: 25.6] [Reference Citation Analysis]
603 Mahmoud AM, Mohammed HM, Khadrawy SM, Galaly SR. Hesperidin protects against chemically induced hepatocarcinogenesis via modulation of Nrf2/ARE/HO-1, PPARγ and TGF-β1/Smad3 signaling, and amelioration of oxidative stress and inflammation. Chemico-Biological Interactions 2017;277:146-58. [DOI: 10.1016/j.cbi.2017.09.015] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
604 Liu P, Chen L, Zhang H. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy. J Immunol Res 2018;2018:1206737. [PMID: 30255103 DOI: 10.1155/2018/1206737] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
605 Ricco G, Cosma C, Bedogni G, Biasiolo A, Guarino M, Pontisso P, Morisco F, Oliveri F, Cavallone D, Bonino F, Plebani M, Brunetto MR. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark 2020;29:189-96. [PMID: 32623383 DOI: 10.3233/CBM-190118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
606 Chen W, Zhou C, Zhang W, Atyah M, Yin Y, Guo L, Tang W, Dong Q, Ye Q, Ren N. Association of WWOX rs9926344 polymorphism with poor prognosis of hepatocellular carcinoma. J Cancer 2018;9:1239-47. [PMID: 29675105 DOI: 10.7150/jca.23808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
607 Smith M, Lara OD, O'Cearbhaill R, Knisely A, McEachron J, Gabor L, Carr C, Blank S, Prasad-Hayes M, Frey M, Jee J, Fehniger J, Wang Y, Lee YC, Isani S, Wright JD, Pothuri B. Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. Gynecol Oncol 2020;159:618-22. [PMID: 33019984 DOI: 10.1016/j.ygyno.2020.09.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
608 Qian Y, Wang B, Ma A, Zhang L, Xu G, Ding Q, Jing T, Wu L, Liu Y, Yang Z, Liu Y. USP16 Downregulation by Carboxyl-terminal Truncated HBx Promotes the Growth of Hepatocellular Carcinoma Cells. Sci Rep 2016;6:33039. [PMID: 27633997 DOI: 10.1038/srep33039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
609 Yip B, Wantuck JM, Kim LH, Wong RJ, Ahmed A, Garcia G, Nguyen MH. Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci 2014;59:192-200. [PMID: 24282055 DOI: 10.1007/s10620-013-2948-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
610 Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, Shi G, Ge Y, Gao P, Yang Y, Ke A, Xiao L, Dong R, Zhu Y, Yang X, Wang J, Zhu T, Yang D, Huang X, Sui C, Qiu S, Shen F, Sun H, Zhou W, Zhou J, Nie J, Zeng C, Stroup EK, Chiu BC, Lau WY, He C, Wang H, Zhang W, Fan J. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68:2195-2205. [PMID: 31358576 DOI: 10.1136/gutjnl-2019-318882] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 29.5] [Reference Citation Analysis]
611 Zhang XF, Chakedis J, Bagante F, Beal EW, Lv Y, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study. World J Surg 2018;42:849-57. [PMID: 28879598 DOI: 10.1007/s00268-017-4199-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
612 Zhang S, Zhou D. Role of the transcriptional coactivators YAP/TAZ in liver cancer. Current Opinion in Cell Biology 2019;61:64-71. [DOI: 10.1016/j.ceb.2019.07.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
613 Yan M, Ha J, Aguilar M, Liu B, Frenette CT, Bhuket T, Wong RJ. Older Patients With Hepatocellular Carcinoma Have More Advanced Disease, Lower Rates of Treatment, and Lower Survival. Journal of Clinical Gastroenterology 2017;51:378-83. [DOI: 10.1097/mcg.0000000000000590] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
614 Mehta R, Tang Qinghe, Tsilimigras DI, Paredes A, Dillhoff M, Cloyd JM, Ejaz A, Tsung A, Spolverato G, Pawlik TM. Long-term outcomes after resection of alcohol-related versus hepatitis-related hepatocellular carcinoma: A SEER-Medicare database analysis. Am J Surg 2021;222:167-72. [PMID: 33131693 DOI: 10.1016/j.amjsurg.2020.10.033] [Reference Citation Analysis]
615 Cottarel J, Plissonnier ML, Kullolli M, Pitteri S, Clément S, Millarte V, Si-Ahmed SN, Farhan H, Zoulim F, Parent R. FIG4 is a hepatitis C virus particle-bound protein implicated in virion morphogenesis and infectivity with cholesteryl ester modulation potential. J Gen Virol 2016;97:69-81. [PMID: 26519381 DOI: 10.1099/jgv.0.000331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
616 Litmanovich A, Khazim K, Cohen I. The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice. Oncol Ther 2018;6:109-27. [PMID: 32700032 DOI: 10.1007/s40487-018-0089-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
617 Panebianco C, Saracino C, Pazienza V. Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression. Tumour Biol 2014;35:7307-15. [PMID: 24833096 DOI: 10.1007/s13277-014-2075-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
618 Wang L, Yao M, Dong Z, Zhang Y, Yao D. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol. 2014;35:9-20. [PMID: 24006223 DOI: 10.1007/s13277-013-1141-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
619 Cebola I. Liver gene regulatory networks: Contributing factors to nonalcoholic fatty liver disease. Wiley Interdiscip Rev Syst Biol Med 2020;12:e1480. [PMID: 32020788 DOI: 10.1002/wsbm.1480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
620 Tanaka T, Okuyama-Dobashi K, Murakami S, Chen W, Okamoto T, Ueda K, Hosoya T, Matsuura Y, Ryo A, Tanaka Y, Hagiwara M, Moriishi K. Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation. Antiviral Res 2016;133:156-64. [PMID: 27515132 DOI: 10.1016/j.antiviral.2016.08.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
621 Moore MS, Bocour A, Tran OC, Qiao B, Schymura MJ, Laraque F, Winters A. Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001-2012. Open Forum Infect Dis 2018;5:ofy144. [PMID: 30019001 DOI: 10.1093/ofid/ofy144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
622 Rajiu V, Balaji P, Sheena TS, Akbarsha MA, Jeganathan K. Doxorubicin-Anchored Curcumin Nanoparticles for Multimode Cancer Treatment against Human Liver Carcinoma Cells. Part Part Syst Charact 2015;32:1028-42. [DOI: 10.1002/ppsc.201500098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
623 Rich N, Tanriover B, Singal AG, Marrero JA. Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma. Transplantation. 2017;101:e12-e19. [PMID: 28009759 DOI: 10.1097/tp.0000000000001515] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
624 Dächert C, Gladilin E, Binder M. Gene Expression Profiling of Different Huh7 Variants Reveals Novel Hepatitis C Virus Host Factors. Viruses 2019;12:E36. [PMID: 31905685 DOI: 10.3390/v12010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
625 Chen W, Xiao W, Zhang K, Yin X, Lai J, Liang L, Chen D. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Sci Rep 2016;6:22976. [PMID: 26964667 DOI: 10.1038/srep22976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
626 Lee J. Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma. Korean J Physiol Pharmacol. 2013;17:375-383. [PMID: 24227937 DOI: 10.4196/kjpp.2013.17.5.375] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
627 Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. AIDS 2017;31:875-84. [DOI: 10.1097/qad.0000000000001424] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
628 Shi M, Chen MS, Sekar K, Tan CK, Ooi LL, Hui KM. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer. 2014;50:928-936. [PMID: 24332572 DOI: 10.1016/j.ejca.2013.11.026] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
629 Gong DY, Chen EQ, Huang FJ, Leng XH, Cheng X, Tang H. Role and functional domain of hepatitis B virus X protein in regulating HBV transcription and replication in vitro and in vivo. Viruses. 2013;5:1261-1271. [PMID: 23698398 DOI: 10.3390/v5051261] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
630 Golabi P, Jeffers T, Younoszai Z, Otgonsuren M, Sayiner M, Mishra A, Venkatesan C, Younossi ZM. Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. Ann Hepatol 2017;16:555-64. [PMID: 28611258 DOI: 10.5604/01.3001.0010.0290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
631 Chen J, Qian Z, Li F, Li J, Lu Y. Integrative Analysis of Microarray Data to Reveal Regulation Patterns in the Pathogenesis of Hepatocellular Carcinoma. Gut Liver 2017;11:112-20. [PMID: 27458175 DOI: 10.5009/gnl16063] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
632 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
633 Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open 2019;9:e029066. [PMID: 31383704 DOI: 10.1136/bmjopen-2019-029066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
634 Pan Z, Pan H, Zhang J, Yang Y, Liu H, Yang Y, Huang G, Ni J, Huang J, Zhou W. Lentivirus mediated silencing of ubiquitin specific peptidase 39 inhibits cell proliferation of human hepatocellular carcinoma cells in vitro. Biol Res 2015;48:18. [PMID: 25889525 DOI: 10.1186/s40659-015-0006-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
635 Schütte K, Schulz C, Malfertheiner P. Nutrition and Hepatocellular Cancer. Gastrointest Tumors 2016;2:188-94. [PMID: 27403413 DOI: 10.1159/000441822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
636 Yao M, Pan LH, Yao DF. Glypican-3 as a specific biomarker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015;14:122-123. [PMID: 25865682 DOI: 10.1016/s1499-3872(15)60350-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
637 Takeda M, Sakaguchi T, Hiraide T, Shibasaki Y, Morita Y, Kikuchi H, Ikegami K, Setou M, Konno H, Takeuchi H. Role of caveolin-1 in hepatocellular carcinoma arising from non-alcoholic fatty liver disease. Cancer Sci 2018;109:2401-11. [PMID: 29896915 DOI: 10.1111/cas.13659] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
638 Schütte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, Malfertheiner P. Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer 2012;1:257-66. [PMID: 24159590 DOI: 10.1159/000343840] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
639 Bai AH, Cheng AS. Alliance of epigenetic forces for the activation of oncogenic Wnt/β-catenin signaling: Editorials. J Gastroenterol Hepatol 2013;28:383-5. [DOI: 10.1111/jgh.12090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
640 Koh S, Tan AT, Li L, Bertoletti A. Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future. Diseases 2016;4:E10. [PMID: 28933390 DOI: 10.3390/diseases4010010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
641 Xu L, Wu J, Lu W, Yang C, Liu H. Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Transplant Proc. 2019;51:3338-3346. [PMID: 31732203 DOI: 10.1016/j.transproceed.2019.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
642 Yang N, Bertoletti A. Advances in therapeutics for chronic hepatitis B. Hepatol Int 2016;10:277-85. [PMID: 26363922 DOI: 10.1007/s12072-015-9661-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
643 Zhao C, Zeng C, Ye S, Dai X, He Q, Yang B, Zhu H. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer. Acta Pharm Sin B 2020;10:947-60. [PMID: 32642404 DOI: 10.1016/j.apsb.2019.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
644 Balasus D, Way M, Fusilli C, Mazza T, Morgan MY, Cervello M, Giannitrapani L, Soresi M, Agliastro R, Vinciguerra M, Montalto G. The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population. Oncotarget 2016;7:86791-802. [PMID: 27888630 DOI: 10.18632/oncotarget.13558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
645 Pinheiro PS, Callahan KE, Stern MC, de Vries E. Migration from Mexico to the United States: A high-speed cancer transition. Int J Cancer 2018;142:477-88. [PMID: 28940515 DOI: 10.1002/ijc.31068] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
646 Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU. Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. Clin Mol Hepatol 2019;25:390-9. [PMID: 31146508 DOI: 10.3350/cmh.2018.0103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
647 Mohamed AA, Omar AAA, El-Awady RR, Hassan SMA, Eitah WMS, Ahmed R, Khater A, Tantawi OMS, Mohamed AA. MiR-155 and MiR-665 Role as Potential Non-invasive Biomarkers for Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C Virus Infection. J Transl Int Med 2020;8:32-40. [PMID: 32435610 DOI: 10.2478/jtim-2020-0006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
648 Wu J, Huang WJ, Xi HL, Liu LY, Wang ST, Fan WZ, Peng BG. Tumor-suppressive miR-3650 inhibits tumor metastasis by directly targeting NFASC in hepatocellular carcinoma. Aging (Albany NY) 2019;11:3432-44. [PMID: 31163018 DOI: 10.18632/aging.101981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
649 Cao J, Li D. Searching for human oncoviruses: Histories, challenges, and opportunities. J Cell Biochem 2018;119:4897-906. [PMID: 29377246 DOI: 10.1002/jcb.26717] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
650 Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12:292-302. [PMID: 25308752 DOI: 10.1038/cmi.2014.91] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 12.1] [Reference Citation Analysis]
651 Cai C, Xie Y, Wu L, Chen X, Liu H, Zhou Y, Zou H, Liu D, Zhao Y, Kong X, Liu P. PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma. Sci Rep 2017;7:46250. [PMID: 28387375 DOI: 10.1038/srep46250] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
652 Tsai JF, Chen SC, Lin ZY, Dai CY, Huang JF, Yu ML, Chuang WL. Interactive effects between Lymphotoxin α +252 polymorphism and habits of substance use on risk of hepatocellular carcinoma. Kaohsiung J Med Sci 2017;33:334-8. [PMID: 28738973 DOI: 10.1016/j.kjms.2017.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
653 Royse KE, El-Serag HB, Chen L, White DL, Hale L, Sangi-Haghpeykar H, Jiao L. Sleep Duration and Risk of Liver Cancer in Postmenopausal Women: The Women's Health Initiative Study. J Womens Health (Larchmt) 2017;26:1270-7. [PMID: 28933583 DOI: 10.1089/jwh.2017.6412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
654 Yao M, Wang L, Yang J, Yan X, Cai Y, Yao D. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. Tumor Biol 2016;37:14677-86. [DOI: 10.1007/s13277-016-5296-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
655 Ezzikouri S, Elfihry R, Chihab H, Elmessaoudi-Idrissi M, Zaidane I, Jadid FZ, Karami A, Tahiri M, Elhabazi A, Kabine M, Chair M, Pineau P, Benjelloun S. Effect of MBOAT7 variant on hepatitis B and C infections in Moroccan patients. Sci Rep 2018;8:12247. [PMID: 30116012 DOI: 10.1038/s41598-018-30824-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
656 Hsu HT, Sung MT, Lee CC, Kuo YJ, Chi CW, Lee HC, Hsia CY. Peroxisome Proliferator-Activated Receptor γ Expression Is Inversely Associated with Macroscopic Vascular Invasion in Human Hepatocellular Carcinoma. Int J Mol Sci 2016;17:E1226. [PMID: 27483249 DOI: 10.3390/ijms17081226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
657 Jones SA, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother 2013;57:4181-9. [PMID: 23774432 DOI: 10.1128/AAC.00599-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
658 Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I, Pinna AD, Golfieri R. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36:729-736. [PMID: 26604044 DOI: 10.1111/liv.13029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
659 Kovesdi I, Bakacs T. Therapeutic Exploitation of Viral Interference. Infect Disord Drug Targets. 2020;20:423-432. [PMID: 30950360 DOI: 10.2174/1871526519666190405140858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
660 Villani R, Cavallone F, Sangineto M, Fioravanti G, Romano AD, Serviddio G. Management of intermediate-stage hepatocellular carcinoma in the elderly with transcatheter arterial chemoembolization failure: Retreatment or switching to systemic therapy? Int J Clin Pract 2021;75:e13733. [PMID: 32981175 DOI: 10.1111/ijcp.13733] [Reference Citation Analysis]
661 Lobaina Y, Perera Y. Implication of B23/NPM1 in Viral Infections, Potential Uses of B23/NPM1 Inhibitors as Antiviral Therapy. IDDT 2019;19:2-16. [DOI: 10.2174/1871526518666180327124412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
662 Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:697-709. [PMID: 30702196 DOI: 10.1111/jvh.13068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
663 van Ginkel WG, Pennings JP, van Spronsen FJ. Liver Cancer in Tyrosinemia Type 1. Adv Exp Med Biol 2017;959:101-9. [PMID: 28755188 DOI: 10.1007/978-3-319-55780-9_9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
664 Zhao L, Zhang Y, Zhang Y. Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-κB axis. J Cell Physiol 2018;233:6661-70. [PMID: 29319182 DOI: 10.1002/jcp.26446] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 7.7] [Reference Citation Analysis]
665 Chen Y, Zhou Q, Li X, Wang F, Heist K, Kuick R, Owens SR, Wang TD. Ultrasmall Paramagnetic Iron Oxide Nanoprobe Targeting Epidermal Growth Factor Receptor for In Vivo Magnetic Resonance Imaging of Hepatocellular Carcinoma. Bioconjugate Chem 2017;28:2794-803. [DOI: 10.1021/acs.bioconjchem.7b00501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
666 Liu KY, Wang LT, Hsu SH, Wang SN. Homeobox Genes and Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E621. [PMID: 31058850 DOI: 10.3390/cancers11050621] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
667 Qi JH, Wang J, Chen J, Shen F, Huang JT, Sen S, Zhou X, Liu SM. High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in Chinese patients. BMC Cancer 2014;14:643. [PMID: 25176041 DOI: 10.1186/1471-2407-14-643] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis